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Numerous recent studies have shown that epigenetic modifications play a 
significant role in cancer pathogenesis. The PADs are a family of epigenetic 
enzymes that catalyze citrullination, a reaction by which PADs convert 
peptidyl-arginine to neutral citrulline, leading to the disruption of protein-protein 
interactions. Our lab has found that PAD2 has a critical role in breast cancer 
progression. The goal of this thesis research was to further elucidate the role 
of PAD2 in epithelial carcinogenesis using PAD2 overexpression tumor cell 
lines and a MMTV-FLAG-hPAD2 transgenic mouse model. We also aimed to 
evaluate how PAD2 may play a direct role in regulating chronic inflammation 
via macrophage extracellular chromatin trap release (“ETosis”). 
 
Interestingly, we found that 40% of the MMTV-FLAG-hPAD2 overexpressing 
transgenic mice developed proliferative skin lesions after five months of age. 
The tumors expressed the transgenic form of FLAG-hPAD2 and showed 
increased expression for inflammatory cytokines such as IL6 and IL8. As the 
next step we conducted a two-stage chemical carcinogenesis study to further 
 evaluate the predilection of MMTV-FLAG-hPAD2 mice to develop more 
invasive skin tumors and compare the histopathology of these tumors with the 
WT tumors. We found that a higher percentage of MMTV-FLAG-hPAD2 mice 
developed skin papillomas and the transgenic tumors were more invasive. 
Furthermore, hPAD2 expression levels were highly positively correlated with 
chemokine levels and negatively correlated with the cell adhesion markers 
suggesting the role of PAD2 in assisting epithelial-mesenchymal transition. 
 
We had previously shown that PAD4 isozyme in neutrophils is involved in 
chromatin decondensation and extracellular chromatin trap release. In this 
thesis research we provide evidence on how PAD2 is involved in macrophage 
extracellular trap (MET) release. Using in vitro macrophage culture models, we 
found that PAD2 is critical in functional MET release and that METs contain 
high levels of histone H4 citrulline 3 (H4Cit3) modification. Using human 
tongue SCC tissue, we show that CD68+ macrophage associated ETs exist in 
tumor tissue and are highly positive for citrullinated histones. Additionally, we 
show that PAD2-rich macrophages associated with chronic subclinical 
inflammation in adipose tissue also release METs suggesting the significant 
role of PAD2 in chronic inflammation via MET release. Collectively, these 
studies provide strong experimental evidence establishing PAD2 as a potential 
oncogene, a therapeutic target for immunomodulation and a regulator of 
obesity and tumor associated inflammation. 
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CHAPTER ONE 
INTRODUCTION: POTENTIAL ROLE OF PEPTIDYLARGININE DEIMINASE 
ENZYMES (PADS) AND PROTEIN CITRULLINATION IN CANCER 
PATHOGENESIS 
 
Chapter reprinted from: Sunish Mohanan; Brian D. Cherrington; Sachi 
Horibata; John L. McElwee; Paul R. Thompson; Scott A. Coonrod. Potential 
role of peptidylarginine deiminase Enzymes (PADs) and protein citrullination in 
cancer pathogenesis.  Biochemistry Research International.  
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PMC3457611. 
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1.1 Abstract 
The peptidylarginine deiminases (PADs) are a family of post-translational 
modification enzymes that catalyze the conversion of positively charged 
protein-bound arginine and methylarginine residues to the uncharged, non-
standard amino acid citrulline. This enzymatic activity is referred to as 
citrullination or, alternatively, deimination. Citrullination can significantly affect 
biochemical pathways by altering the structure and function of the target 
proteins. Five mammalian PAD family members (PADs 1-4 and 6) have been 
described and show tissue-specific distribution patterns and function. Recent 
reviews on PADs have focused on their role in autoimmune diseases such as 
rheumatoid arthritis, psoriasis, and multiple sclerosis. Here, we will discuss the 
potential role of PADs in tumor progression and tumor-associated 
inflammation. In the context of cancer, increasing clinical evidence suggests 
that PAD4, and possibly PAD2, have important roles in tumor progression. 
The link between PADs and cancer is strengthened by recent findings showing 
that treatment of cell lines and mice with PAD inhibitors significantly 
suppresses tumor growth and, interestingly, inflammatory symptoms. At the 
molecular level, transcription factors, co-regulators, and histones, are 
functional targets for citrullination by PADs, and citrullination of these targets 
can affect gene expression in multiple tumor cell lines. As the novel 
relationship between PADs, inflammation, and cancer unfolds, next generation 
isozyme-specific PAD inhibitors may have therapeutic potential to regulate 
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both the inflammatory tumor microenvironment and tumor cell growth.   
 
1.2 Introduction 
PAD-mediated citrullination can alter the tertiary structure of target substrates 
and/or alter protein-protein interactions; thus affecting various cellular 
processes1, 2 (Figure 1.1). 
 
Recently, protein citrullination has garnered increased attention due to its role 
in the pathogenesis of various inflammatory conditions such as rheumatoid 
arthritis (RA), multiple sclerosis, psoriasis, chronic obstructive pulmonary 
disease (COPD), neurodegenerative diseases and, also, due to its emerging 
role in various human and animal cancers 3-7.  In this essay, we will first briefly 
discuss the tissue-specificity and hormonal regulation of the five PAD isoforms 
and then focus on the potential role of this enzyme family in carcinogenesis, 
tumor progression and inflammation.  
 
1.3 Tissue expression patterns and substrate specificity of PAD family 
members 
PADs are Ca2+-dependent enzymes and there are five different isozymes in 
mammals; namely PAD1, 2, 3, 4, and 6 8, 9. The PAD genes likely arose by 
duplication of the ancestral homologue, PAD2, and are localized to a well-
organized gene cluster at 1p36.13 in humans. Interestingly, this locus is also 
predicted to contain a novel, yet to be defined, tumor suppressor protein 10.  
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PAD enzymes are highly homologous, with ~50-60 percent sequence identity 
at the amino acid level. Although there is some overlap with respect to target 
proteins, each family member also appears to target a unique set of cellular 
proteins as well 11, 12.  Additionally, as described below, each family member 
also exhibits a tissue-selective distribution pattern. We note here that, in this 
review, we will be using the more commonly utilized gene synonym, PAD, 
while the approved HUGO Gene Nomenclature Committee gene names for 
the family members are actually PADI1, PADI2, PADI3, PADI4, and PADI6.  
PAD1 appears to primarily be expressed in the epidermis and uterus.  In the 
epidermis, PAD1 citrullinates cytokeratin and this modification is important for 
modulating the cornification of the epidermis and maintaining the barrier 
function of superficial keratinized epidermal cell layers. The loss of charge 
following citrullination of cytokeratin causes disassembly of the cytokeratin-
filaggrin complex and proteolytic degradation of these targets.  
 
PAD2 is expressed in multiple organs, including the brain, female reproductive 
tissues, skeletal muscle, and cells of the hematopoietic lineage. In the brain, a 
major target for PAD2 is myelin basic protein (MBP), a constituent of the 
myelin sheath 13, 14. Citrullination of MBP by PAD2 likely plays a key role in the 
pathogenesis of neurodegenerative disease 15. PAD2 can also citrullinate the 
intermediate filament vimentin in macrophages 16, leading to cytoskeletal 
disintegration and eventually apoptosis. In female reproductive tissues, PAD2 
levels appear to be regulated by hormones, predominantly estrogen, and also 
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possibly by epidermal growth factor 17. PAD2 has also been found to be 
expressed in human mammary gland epithelial cells, with a fraction of PAD2 in 
these cells localizing to the nucleus and binding directly to chromatin 18. In 
canine mammary tissue, histone citrullination levels closely correlate with the 
expression of PAD2 across the estrous cycle, suggesting that PAD2 may 
target histones for citrullination in this tissue 17. In support of this prediction, a 
recent study has found that PAD2-catalyzed citrullination of histone H3 
arginine 26 can regulate estrogen receptor α target gene activity 19.  
 
PAD3 expression is highly restricted to the hair follicle and epithelium and a 
major target for PAD3 is trichohyaline. Additionally PAD3 can also citrullinate 
filaggrin leading to altered epidermal homeostasis and loss of barrier function 
20. 
PAD4 is expressed in hematopoietic progenitor cells, immune cells such as 
granulocytes, monocytes and macrophages, natural killer cells, and carcinoma 
cells originating from lung, esophagus, lung, breast, and ovary 5, 21. PAD4 is 
often localized to the nucleus and is the only PAD family member with a 
canonical nuclear localization sequence 22. Antithrombin has been found to be 
an extracellular PAD4 substrate 23 and citrullination of this target suppresses 
the ability of antithrombin to inhibit thrombin 24. Increased thrombin activity is 
considered to be a hallmark of cancer by promoting angiogenesis, increased 
tumor growth, and distant metastasis.  
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Figure 1.1: Peptidylarginine deiminase (PAD) enzymes catalyze the 
conversion of protein arginine residues to citrulline. 
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Interestingly, citrullinated anti-thrombin levels are elevated in serum samples 
from patients with malignant cancers, thus raising the possibility that PADs 
may affect tumor progression via citrullination of antithrombin 25.   
 
PAD4 also appears to function as a transcriptional coregulator for a range of 
factors such as p53, ELK1, p300, p21, CIP1, nucleophosmin and ING4 26-30. 
While the mechanism by which PAD4 regulates target gene activity is not 
entirely clear, Edman degradation and analysis using site-specific anti-
citrullinated histone antibodies has found that PAD4 can target the N-terminal 
tails of histones H2A, H3, and H4 for citrullination. More specifically, PAD4 has 
been found to directly citrullinate histone H4 and H2A at arginine 3, and 
histone H3 at arginines 2, 8, 17, and 26. Histone tail citrullination has been 
found to promote chromatin decondensation in vitro and in vivo 31, 32. Thus, it 
seems likely that the gene regulatory role of PAD4 is mediated by its initial 
recruitment to target promoters by the relevant transcription factor, followed by 
subsequent deimination of specific residues in the N-terminal histone tails, 
leading to local changes in chromatin architecture and modulation of target 
gene expression (Figure 1.2).  PAD4 is both a corepressor and coactivator of 
gene transcription and also appears to contribute to epigenetic cross-talk 33 
during DNA damage by acting in concert with histone deacetylase 2 (HDAC2) 
to regulate p53 target gene activity 34.  
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Figure 1.2: PAD mediated histone tail citrullination leads to chromatin 
decondensation. 
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Following DNA damage, PAD4 and HDAC2 separate from the p53-target gene 
promoters such as p21, GADD45, and PUMA, resulting in an increased 
incidence of histone Lys acetylation and Arg methylation at these sites.  
 
PAD6 is a maternal effect gene that is specifically expressed in oocytes and 
pre-implantation embryos and is essential for embryonic development beyond 
the 2-cell stage 35. To date, there has been little evidence that this ovarian 
PAD isozyme is involved in cancer. Interestingly, however, a genome-wide 
SNP association in Icelanders showed a significant correlation between 
cutaneous basal cell carcinoma risk and mutations in the PAD4/PAD6 locus at 
1p36 36. The importance of this PAD family member in developmental biology 
is reviewed elsewhere 37, 38 and will not be discussed further in this review. 
 
1.4 Hormonal regulation of PADs 
Early PAD biological studies focused mainly on the expression patterns of the 
different family members in reproductive tissues and also on their catalytic 
activity at these sites. Outcomes from these studies showed that anterior 
pituitary-localized rat lactotroph cells express PAD2 in a sexually dimorphic 
fashion, with expression confined to the female. Additional studies showed 
that PADs 1, 2, and 4 are present in uterine tissue and that protein 
citrullination is extensive in the uterine epithelium in an estrus cycle-dependent 
manner 39, 40.  More recently, studies have found that mouse, dog, and human 
mammary glands express both PAD2 and 4 in luminal epithelial cells 17.   
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Pituitary gland and uterus 
In the female rat pituitary, PAD enzymatic activity is highest during proestrus 
and estrus when serum estrogen levels are at their peak 39, 41.  Ovariectomy of 
rats suppressed PAD activity in pituitary lysates, but activity could be restored 
by injection of exogenous estrogen.  Furthermore, treatment of the pituitary-
derived MtT/S cell line with estrogen results in a dose-dependent increase in 
PAD expression and activity 42.  Together, these observations suggest that 
estrogen directly influences PAD expression and activity in the pituitary.  Given 
that estrogen primes lactotrophs for prolactin biosynthesis, PAD enzymatic 
activity may play an important role in this normal physiological process, and 
may also promote pituitary neoplastic growth.  
 
Our examination of Massively Parallel Signature Sequencing (MPSS) 
transcriptome data (GEO Profiles GDS868) indicates that PADs 1, 2, and 4 
expression levels are highest in the mouse uterus as compared to the 50 other 
tissues examined 43. Furthermore, analysis of cDNA microarray data from 
Hewitt et al. shows that PAD1, 2, and 4 mRNA appear to be estrogen 
regulated 44. In the uterus, the distribution of these isozymes appears to be 
primarily limited to glandular and luminal epithelial cells and also displays an 
estrous cycle-dependent regulation pattern, with the highest expression of 
these family members occurring during estrus 45, 46.  Similar to the pituitary, 
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PAD2 and PAD4 expression and activity in the uterus is lost following 
ovariectomy, but can be restored by injection of exogenous estrogen, 
indicative of estrogen regulation 45, 46. Given the known mitogenic properties of 
estrogen in female cancers, it is possible that estrogen-induced upregulation 
of PAD expression and activity in the uterus may promote neoplastic growth in 
this tissue.  However, a potential role for PADs in pituitary and uterine tumor 
progression has yet to be investigated.  
 
Mammary gland 
Protein and mRNA expression studies in canine mammary glands collected at 
various stages of the estrous cycle show that PAD2 expression initiates during 
estrus, with mRNA and protein levels peaking during diestrus.  In the mouse 
mammary gland PAD2 and 4 expression is highest in luminal epithelial cell 
populations during the estrus 17, 46. This species-specific difference in 
expression levels may reflect differences in estrous cycle stage lengths and 
hormone levels between species. Ovariectomy in mice also results in loss of 
PAD2 and 4 expression in the mammary gland, thus further corroborating the 
role of estrogen in PAD expression in female reproductive tissues.  Molecular 
studies show that treatment of MCF-7 cells with estrogen rapidly induced the 
upregulation of PAD4 and the involvement of estrogen in PAD4 expression in 
mammary epithelial cells appears to be mediated by two upstream estrogen 
response elements (designated ERE -125 and -126) which are bound by ERα 
 12 
 
following estrogen treatment. Furthermore, this study showed that the ERα-
dependent increase in PAD4 expression can also be mediated by estrogen 
signaling to the PAD4 proximal promoter via cross talk with the AP-1, Sp-1, 
and NF-Y transcription factors 47. 
 
1.5 PAD4 mediated histone tail citrullination: An emerging role for PADs 
in gene regulation and cancer 
PAD4 has also been found to regulate estrogen receptor target gene activity 
following estrogen stimulation via histone tail citrullination 48. Given the role of 
estrogen as a mitogen in cancer cells, this observation provides a clear 
potential link between PAD activity and cancer growth. In addition to estrogen, 
another mitogen, EGF, has been shown to utilize PAD4 as a cofactor to 
activate target gene activity. Zhang e.t al. documented that treatment of MCF-
7 cells with EGF leads to PAD4-mediated citrullination of the ELK1 oncogene. 
This citrullination event then facilitated subsequent phosphorylation of ELK1 
by ERK1/2, which, in turn, promoted histone acetylation and subsequent 
activation of a range of targets including the immediate early gene, c-fos 30.  
PAD4 has also been found to interact with the major tumor suppressor, p53, 
and affect the expression of p53 target genes such as p21, OKL38, CIP1 and 
WAF1 26-30.  Interestingly, a recent study also found that citrullination levels at 
histone H4 arginine 3 (H4R3) are inversely correlated with p53 protein 
expression and with tumor size in non-small cell lung cancer tissues 32. The 
authors also demonstrated that the p53–PAD4 pathway leads to citrullination 
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of H4R3 and Lamin C in response to DNA damage and nuclear fragmentation. 
They also found that PAD4-mediated H4R3 citrullination appears to lead to 
localized chromatin decondensation around sites of DNA damage, thus 
facilitating p53-mediated cell death. In vivo studies then demonstrated that 
even though PAD4-null mice were grossly normal with regard to organ 
morphologies, they appeared resistant to apoptotic stimuli and also showed a 
consistent reduction in cleaved caspase-3 expression. The authors conclude 
that the histone H4 citrulline 3 (H4Cit3) modification may form a novel 
“apoptotic code” which could potentially be used to detect a range of damaged 
cells, including tumor cells, following treatment of patients with cancer 
therapies. It is interesting to note, however, that the PAD inhibitor Cl-amidine 
increases p53 levels both in cell culture and in inflammatory cells isolated from 
mice treated with this compound 29, 49.  Reconciling these two disparate 
observations requires further study. In support of a role for the H4Cit3 
modification in marking apoptotic tumor cells, recent immunofluorescence 
studies in our lab found that citrullination at H4R3 was very robust within the 
nucleus of epithelial cells undergoing morphological changes associated with 
various stages of apoptosis in comedo-DCIS xenograft sections  (Figure 1.3). 
These xenografts were generated from MCF10DCIS cell line which belongs to 
the group of MCF10AT tumor progression series of cell lines 50, 51.  
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Figure 1.3: H4cit3 (green) immunostaining of DCIS xenograft sections. 
Nuclei are stained with DAPI (blue). Dotted line demarcates the area adjacent 
to the central necrotic core of the comedo-DCIS lesion. (Magnification 400X) 
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From a more clinical perspective, recent immunohistochemical and western 
blot studies have found that PAD4 appears to be overexpressed in several 
types of invasive carcinomas 5, 52, 53. Outcomes from these studies found that 
PAD4 expression and, frequently activity, was elevated in neoplastic cells from 
breast carcinomas, lung adenocarcinomas, hepatocellular carcinomas, 
esophageal carcinomas with squamous differentiation, colorectal 
adenocarcinomas, renal carcinomas, ovarian adenocarcinomas, uterine 
carcinomas, uterine adenocarcinomas and bladder carcinomas 52. However, 
PAD4 expression was absent or minimal in the following tumors: benign 
gastric and uterine leiomyomas, hyperplastic conditions of endometrium, 
cervical polyps, teratomas, hydatidiform moles, hemangiomas, lymphatic 
proliferative conditions, schwannomas and neurofibromas 5. Consistent with 
the PAD4 protein expression pattern in carcinomas, the same patients also 
had elevated serum PAD4 activity and citrullinated anti-thrombin levels. Taken 
together these observations support the potential use of this enzyme as a 
clinical prognostic biomarker.   
 
1.6 PAD2 and cancer pathogenesis 
Given the volume of recent literature linking PAD4 with gene regulation in 
cancer cells, a role for this family member in tumor progression seems likely. 
Comparative studies evaluating PAD2 expression in mammary carcinomas 
from humans, dogs, and cats shows that the nuclear localization of PAD2 may 
also prove to be associated with tumor progression.  Normal human, canine, 
 16 
 
and feline mammary tissue shows strong nuclear and cytoplasmic PAD2 
staining, but as tumors progress there is a general reduction in the nuclear 
localization of PAD2 (Figure 1.4 and 1.5) 54.  In the mammary gland, PAD2 
expression is specific to cytokeratin positive luminal type epithelial cells 
(Figure 1.5).  Thus, the loss of nuclear PAD2 may result in alterations in gene 
expression that lead to neoplastic transformation.  It is interesting to note that 
a subset of invasive breast carcinomas tend to retain strong cytoplasmic and 
nuclear expression of PAD2.  Further characterization of this subclass of 
tumors with regard to function of PAD2 is warranted as isozyme specific PAD 
inhibitors may be of use in combinatorial therapies to treat such tumor types.  
Given these new findings, and PAD4’s documented role in cancer biology, it 
will be interesting to determine whether PAD2 and PAD4 may function in a 
synergistic manner to promote tumor progression. The observation that both 
PAD2 and PAD4 expression appears to be regulated at some level by 
estrogen, suggests that these two PADs may work together to mediate the 
estrogen response. The observations that PAD2 expression in mammary 
epithelial cells is induced by EGF 17, and that PAD4 regulates EGF-induced 
ELK1 target gene activation, suggests that PAD2 and PAD4 may also 
cooperate to mediate EGFR signaling 30.   
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Figure 1.4: PAD2 IHC staining of the normal human mammary gland, a 
DCIS lesion, and invasive carcinomas.  Nuclear staining intensity is reduced 
in most invasive tumors while a subset of these tumors retains strong PAD2 
staining. The sections are counterstained with hematoxylin (Magnification 
200X) 
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Figure 1.5: PAD2 (green) is expressed in luminal epithelial cells of 
preinvasive, invasive, and metastatic human mammary tumors.  
Cytokeratin (red) staining differentiates luminal epithelial type from 
myoepithelial cells. (Magnification 400X) 
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1.7 PAD inhibitors block cancer progression 
In further support of a role for PADs in tumor growth, several recent reports 
have also shown that treatment of cancer cell lines with PAD inhibitors 
decreases cancer cell viability without affecting the growth of normal cells 55. 
Cl-amidine 56, and the related PAD4 inhibitor, F-amidine 57, display low 
micromolar cytotoxicity towards various tumor cell lines such as U2OS cells, 
HL-60, HT-29, and MCF-7 29, 55, 58.  These compounds also can induce the 
differentiation of HL-60 cells, a leukemic cell line, making these cells more 
susceptible to drug treatments 55. Cl-amidine can also act synergistically with 
the anticancer drug doxorubicin, thus enhancing the efficiency of cell death 
following a simultaneous treatment with these two compounds. In tumor cell 
lines such as MCF-7 cells, Cl-amidine also regulates the expression of the 
tumor suppressor protein OKL38 in a p53-dependent manner by decreasing 
histone citrullination at the OKL38 promoter 28, 29.   
 
A recent study, using a Cl-amidine derivative with increased cell permeability, 
YW3-56 (Figure 1.6), found that this drug significantly suppressed cancer cell 
growth and also reduced tumor size in mouse xenograft models of sarcoma 59. 
Furthermore, this compound affected the expression of genes related to cell 
proliferation and cell death and was also found to regulate macro-autophagy in 
cancer cells. Mechanistically, the authors discovered that the drug likely 
targeted factors within the mTORC1 pathway for inhibition. These studies, as 
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well as the demonstration that PAD inhibitors are well tolerated in multiple 
different mouse disease models 49, 60, underscores the potential of PAD 
inhibitors as novel epigenetic anticancer drugs.  Given that Cl-amidine, F-
amidine, and YW3-56 display limited selectivity (Figure 1.6), it is unclear 
whether the inhibition of one or more PADs is required for the in vivo effects of 
these compounds.  The development of new, more selective compounds, such 
as the PAD4 selective inhibitor TDFA and the PAD1 selective inhibitor o-F-
amidine (Figure 1.6), will undoubtedly prove to be useful for sorting this issue 
out.  
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Figure 1.6: PAD inhibitors and their selectivity (TDFA - Threonine-
aspartate-F-amidine; TDCA - Threonine-aspartate-Cl-amidine)
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1.8 PAD-mediated citrullination: Linking inflammation with cancer 
progression? 
 
Role of inflammation in cancer progression 
Chronic inflammation is involved in the progression and recurrence of many 
types of cancer, including breast cancer. Epidemiological studies have 
documented that high levels of circulating acute phase inflammation-
associated proteins at 3 years post-treatment are associated with an elevated 
risk for subsequent tumor recurrence and mortality in women 61. Several 
studies have also demonstrated direct links between circulating inflammatory 
markers and progression to metastatic breast cancer 62-66.  Additionally, pro-
inflammatory cytokines are well known for promoting tumor growth and 
facilitating metastasis by altering the tumor cell phenotype and by regulating 
stromal cells (endothelial cells, tumor-associated macrophages, and 
fibroblasts) within the tumor microenvironment.  Furthermore, infiltrating 
immune cells within the tumor itself can promote tumorigenesis 67. These 
findings suggest that the mechanisms by which inflammation in the tumor 
microenvironment drives metastasis is both intimately linked and 
fundamentally different to the primary mechanisms driving carcinogenesis 68.  
 
Role of PADs in inflammation 
As noted earlier, numerous studies have documented increased protein 
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citrullination within inflamed tissues from patients with autoimmune diseases 
such as rheumatoid arthritis and colitis 3, 4, 69. More recently, these 
inflammatory symptoms have been shown to be suppressed by the PAD 
inhibitor, Cl-amidine, in mouse models of colitis and RA 49. Another emerging 
link between PADs and inflammation is the newly defined role for PAD4 in 
catalyzing histone hypercitrullination during Neutrophil Extracellular Trap 
(NET) formation in inflamed tissues. A number of recent reports have shown 
that, following activation, peripheral blood neutrophils form a highly 
decondensed chromatin structure that both captures and kills invading 
pathogens 70-72 . Mechanistically, PAD4 was found to catalyze this dramatic 
chromatin decondensation event via histone tail hypercitrullination 73.  Analysis 
of this process at the ultrastructural level by electron microscopy showed that, 
following PAD4 activation in HL60 granulocytes, these cells show a dramatic 
and rapid conversion of multi-lobular heterochromatic nuclei to a more round 
euchromatic nuclear architecture, suggesting a direct role for PADs in 
heterochromatic-euchromatic interchange 31. These new findings indicate that 
PAD4 can mediate chromatin structure change both at the local and genome-
wide level. 
 
Citrullination of vimentin is correlated with the proliferation of fibroblast-like 
synoviocytes (following isolation from patients with rheumatoid arthritis) and 
also stimulates TNF-α and IL-1 production in these cells 74. Given the links 
between vimentin citrullination, inflammation, and cell proliferation, and given 
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how important cytoskeletal integrity is for cell motility, we hypothesize that 
citrullination of vimentin by PAD enzymes may also affect tumor cell migration 
and promote an inflammatory microenvironment. Additionally, given that PAD2 
can regulate cytokine signaling in macrophages via citrullination of IKKγ (thus 
suppressing NF-kB activity) 75, we predict that PAD-mediated regulation of 
macrophage activity could also potentially affect cross-talk between tumor-
associated macrophages and cancer cells.  
 
While PAD activity has primarily been found to regulate autoimmune-mediated 
inflammatory events, recent studies suggest that PAD-mediated citrullination is 
also elevated in a variety of inflammatory states which lack a strong 
autoimmune component, such as COPD and myositis 76-78. Perhaps the best 
demonstration that PAD-mediated citrullination can facilitate non-autoimmune 
or microbial-induced inflammatory events is the recent finding that PAD activity 
is strongly upregulated in inflamed tissue following a sterile skin punch biopsy 
procedure in mice 79. Thus, it can be inferred that PAD-mediated citrullination 
plays a critical and fundamental role in inflammatory events induced by a 
range of pathologies, both infectious and non-infectious.  
 
Role of PADs in chemokine signaling 
PAD2 and PAD4 are highly expressed in peripheral blood mononuclear cells 
such as NK cells, T cells, B cells and monocytes 16 and, thus, are likely to be 
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the main PAD “players” in chemokine signaling.  Chemokines are important for 
the proper recruitment of leukocytes to the site of inflammation. The 
chemokine-receptor system can be dramatically modified in neoplasms, 
especially at the invasive edges, and can act as a pro-angiogenic and a pro-
desmoplastic mediator.  Several chemokines, including CXCL1, 2 and 8 have 
been found to exert effects on tumor cell growth. The CXC group of 
chemokines, with the tripeptide (Glu-Leu-Arg/ELR) at the amino-terminus of 
the CXC motif (ELR+), is pro-angiogenic and stimulates cell migration and 
proliferation. The capacity of chemokines to activate or repress biological 
pathways depends, in part, upon post-translational modifications such as 
glycosylation and on proteolytic processing of the chemokine’s N- or C-
terminus 80.  Importantly, PADs have recently been found to citrullinate 
CXCL5, CXCL8, CCL17, and CCL26 81, thus directly modulating the 
inflammatory milieu. Furthermore, chemokine citrullination does not appear to 
be a rare event in vivo, as, for example, CXCL8 was found to be citrullinated at 
arginine 5 in 14 % of all blood leukocyte derived CXCL8 81. While the role of 
citrullinated chemokines in the inflammatory process is currently coming to 
light, their effect in cancer progression has yet to be investigated. However, 
given the strong links between inflammation and cancer progression, these 
observations support the hypothesis that PAD activity may play an important 
role in regulating the inflammatory milieu of the cancer microenvironment.  
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1.9 Conclusions 
Protein citrullination is emerging as a critical post-translational modification in 
developmental biology, inflammation, and cancer pathogenesis. With respect 
to cancer, PAD enzymes are now being identified as important potential 
players in tumor progression that both regulate transcriptional activity and 
modulate the inflammatory microenvironment via cytokine citrullination. The 
major likely roles of PADs in cancer pathogenesis are summarized in Figure 
1.7. Given these emerging links between PADs and cancer biology, a better 
understanding of the upstream mechanisms that induce PAD expression, and 
the downstream mechanisms by which PADs regulate gene expression and 
inflammatory events will likely advance our understanding of tumor biology.  
Furthermore, the upregulation of specific PAD isozymes and activity at critical 
points of tumor progression raises the possibility that these enzymes, and their 
resulting posttranslational modifications, can function as novel cancer 
biomarkers. Lastly, the observations that (1) PAD inhibitors reduce 
inflammatory symptoms in mouse models of disease, (2) the link between 
PADs, inflammation, and cancer is currently unfolding, and (3) next generation 
isozyme-specific PAD inhibitors are currently being developed, raise the 
possibility that the use of PAD inhibitors in preclinical and clinical cancer 
therapies may soon be realized.   
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Figure 1.7: Potential role of PAD enzymes in cancer pathogenesis. 
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CHAPTER TWO 
HUMAN PAD2 TRANSGENE OVEREXPRESSION LEADS TO 
SPONTANEOUS SKIN NEOPLASIA AND PROMOTES MALIGNANCY AND 
TUMOR-ASSOCIATED INFLAMMATION IN CHEMICALLY INITIATED SKIN 
TUMORS IN MICE   
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2.1 Abstract 
Introduction:  
Peptidylarginine deiminases (PADIs) are a family of posttranslational 
modification enzymes that convert positively charged arginine residues on 
substrate proteins to neutrally charged citrulline. This activity, called 
citrullination or deimination, has been shown to have wide-ranging effects on 
target protein structure, function, and protein-protein interactions. PADI2 has 
been implicated in various diseases, including multiple sclerosis, inflammatory 
diseases such as RA and COPD, and more recently, cancer. We have 
recently reported that PADI2 and HER2 expression is correlated in breast 
cancer cell lines, and that PADI2 plays a role in the proliferation of mammary 
tumors in vitro and in vivo. The goal of this study was to analyze whether the 
transgenic over-expression of PADI2 driven by the MMTV-LTR promoter can 
induce oncogenesis in hormone-responsive epithelium. 
 
Methods: 
To examine whether the overexpression of PADI2 is sufficient to drive 
tumorigenesis in epithelial tissue, we cloned human FLAG-tagged PADI2 
cDNA downstream of the hormone-responsive MMTV-LTR promoter. We 
generated four founder lines in FVB mice expressing the MMTV-FLAG-PADI2 
transgene, and performed phenotypic and genetic analysis of these mice. We 
have created stable cell lines overexpressing FLAG-PADI2 in the human skin 
cancer cell line A431 to validate our findings in the transgenic mice. Lastly, In 
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order to further characterize the rate of tumor formation and histopathological 
properties of skin tumors, in this study we initiated skin tumors in wild type 
(WT) and MMTV-FLAG-hPAD2 mice using a 9,10-dimethyl-1,2-
benzanthracene followed by O-tetradecanoylphorbol-13-acetate (DMBA - 
TPA) chemical carcinogenesis treatment model.  
 
Results: 
The ectopic expression of human PADI2 in mouse epithelium is sufficient to 
promote neoplasia, as we report that ~20% of transgenic mice develop 
proliferative skin lesions. Interestingly we found that in a subset of these mice, 
these lesions further progress to more invasive phenotype such as squamous 
cell carcinomas.  In addition, we note that these skin lesions express high 
levels of transgene, as well as display alteration in markers of EMT 
(decreased E-cadherin) and inflammation (increased IL6/IL8). We further 
confirmed these results in the human squamous cell carcinoma cell line A431, 
where we report that stable over-expression of FLAG-PADI2 increases 
markers of inflammation (IL6/IL8) and EMT, ultimately resulting in increased 
tumor cell invasiveness. No untreated mice developed skin lesions during the 
evaluation period in this study. The MMTV-FLAG-hPAD2 mice developed 
higher number of papillomas with a faster tumor growth rate. More 
significantly, histopathologic analysis showed that in MMTV-FLAG-hPAD2 
mice, skin tumors developed to invasive SCC more frequently than the WT 
controls. The MMTV-FLAG-hPAD2 tumors were highly inflamed with dense 
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inflammatory cell infiltrate and increased markers for tumor-associated 
inflammation and epithelial-mesenchymal transition (EMT). Specifically, 
CCL17, IL6 and murine IL8 homologues  (LIX, MIP2), and the mesenchymal 
marker, Vimentin, were elevated in the transgenic tumors while the cell 
adhesion marker, E-cadherin, expression was decreased compared to the WT 
tumors suggesting the enhanced invasiveness of the transgenic tumors. 
Furthermore, the levels of nuclear phospho-STAT3 (signal transducer and 
activator of transcription 3) were increased in the transgenic tumors which are 
consistent with the IL8 and IL6 downstream signaling in a cytokine rich 
microenvironment.  
 
Conclusion: 
Collectively, these studies provide functional and mechanistic evidence 
establishing PADI2 as a potential novel oncogene in the development of skin 
neoplasia, and might offer a new target for cancer therapy. These data 
suggest that hPAD2 transgene can dramatically increase the malignant 
conversion rate of benign tumors and cause elevated tumor-associated 
inflammation. 
 
Key words: Peptidylarginine deiminase, PAD2/PADI2, MMTV-LTR, MMTV-
FLAG-PADI2, Skin Neoplasia, Squamous Cell Carcinoma, A431, Tumor-
associated Inflammation, EMT 
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2.2 Introduction 
The peptidylarginine deiminase family of posttranslational modification 
enzymes converts positively charged arginine residues on substrate proteins 
to neutrally charged citrulline. This activity, alternatively called citrullination or 
deimination, has been shown to have wide-ranging effects on target protein 
structure, function, and protein-protein interactions.  The PADI enzyme family 
is thought to have arisen by gene duplication and localizes within the genome 
to a highly organized cluster at 1p36.13 in humans. At the protein level, each 
of the five well-conserved PADI members shows a relatively distinct pattern of 
substrate specificity and tissue distribution 1, 2. Increasingly, the dysregulation 
of PADI activity is associated with a range of diseases, including rheumatoid 
arthritis (RA), multiple sclerosis, ulcerative colitis, neural degeneration, COPD, 
and cancer 3-5. While the presumptive function of PADI activity in most 
diseases is linked to inflammation, the role that PADIs play in cancer 
progression is still under investigation. Others have shown that citrullination of 
the p53 tumor suppressor protein by PADI4 affects the expression of p53-
target genes p21, OKL38, CIP1 and WAF1 6-8. While PADI2 has historically 
been defined as a cytoplasmic protein, recent evidence from our lab showed 
that PADI2 can localize to the nucleus and directly bind chromatin to influence 
target gene expression 9-12.  
 
Our recent studies suggest a role for PADI2 in the oncogenic progression of 
breast cancer, more specifically, HER2-positive tumors, as RNA-seq data 
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reveal that PADI2 is highly correlated with HER2/ERBB2 overexpression 
across 57 breast cancer cell lines. We concluded this study with the first 
preclinical evidence showing that the PADI inhibitor, Cl-amidine, could be 
utilized as a therapeutic agent for the treatment of tumors in vivo.  
 
To further investigate the involvement of PADI2 in the oncogenesis of 
epithelial tumors, we generated FVB mice expressing FLAG-PADI2 under the 
control of the hormone-responsive mammary tumor virus (MMTV) promoter. 
However, while transgenic expression of human PADI2 in mammary glands 
was detected, the MMTV-FLAG-PADI2 mice failed to develop any mammary 
tumors. While expression from the MMTV-LTR promoter is normally found to 
be localized to the mammary and salivary gland, other tissues have been 
implicated, including the skin and ovaries 13, 14.  Our results confirm this 
pattern of expression, as we see increased transgenic human PADI2 transcript 
levels in the all four of those tissues. Surprisingly, we discovered that 20% of 
the transgenic mice developed skin proliferative lesions after five months. 
These tumors expressed high levels of transgenic human PADI2 and display 
markers of increased invasiveness and epithelial to mesenchymal transition 
(EMT). Furthermore, some of these tumors display the hallmarks of malignant 
progression to highly invasive squamous cell carcinomas. 
 
Previous studies have reported that three PADI isozymes, PADI1, PADI2, and 
PADI3, re expressed in the epidermis, with all three displaying the ability to 
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target filaggrin for citrullination, a key protein involved in tissue hydration and 
barrier functions 15. PADI1 and PADI3 have been the primary isozymes 
characterized in the epidermis to date; with PADI3 being found to deiminate 
trichohyalin in hair follicles 16, 17 and PADI1 deiminating keratin (K1 and K10) 
and filaggrin during epidermal differentiation 18, 19. Moreover, the 
overexpression of PADI1 (along with PADI2 and PADI3), has been shown to 
generate abnormal levels of citrullinated keratin K1 in the epidermis of 
psoriatic patients 20. This suggests that aberrant expression of PADIs, 
including PADI2, might play a role in diseases of the skin, including cancer.  
 
Interestingly, the original cloning of human PADI2 cDNA was from the human 
skin cancer cell line, HSC-1, which is derived from a cutaneous squamous 
carcinoma 21. We report here a novel model of skin neoplasia in FVB 
transgenic mice, driven by human PADI2 under the MMTV-LTR promoter; 
thus, establishing a novel role for PADI2 in cancer progression. We further 
characterized this novel model of skin neoplasia in MMTV-FLAG-hPAD2 
transgenic mice by conducting a two-stage chemical carcinogenesis study. 
 
DMBA-TPA chemical carcinogenesis model is widely used to test the 
susceptibility of transgenic mice to develop skin neoplasia 22-24. DMBA has 
been shown to induce an irreversible mutation in mouse skin (an A-to-T 
transversion in codon 61 of the oncogene Ha-ras) 25-27. Two stage chemical 
carcinogenesis models use phorbol esters or other mitogenic agents to 
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promote proliferation of an initiated cell. This results in expansion of a clonal 
population of cells which typically develops into benign non-invasive tumors 
such as papilloma. After withdrawal of these agents these benign lesions may 
regress or remain stable 28. This phenomenon allows this model to study 
tumor progression into invasiveness in the presence of a transgene. Tumor 
invasion and metastasis involve evolution of benign tumor cells permitting their 
expansion and growth within a nonphysiological microenvironment 24, 29 
We were also interested in comparing the histopathological features of tumor 
invasiveness, tumor associated inflammation and cytokine levels between the 
transgenic and WT tumors. The significant contribution of inflammation to 
tumor development, progression, and microenvironment regulation has gained 
increased acceptance in recent years 30. we predicted that hPAD2 
overexpressing skin tumors in the DMBA-TPA treated mice also will show 
increased inflammatory cytokine expression and invasiveness compared to 
the WT tumors.   
 
2.3 Materials and Methods 
Generation of MMTV-FLAG-PADI2 mice 
To generate the MMTV-FLAG-PADI2 construct, a human PADI2 cDNA 
fragment was removed from pcDNA3.1-FLAG-PADI2 11, and cloned into the 
EcoRI sites of the MMTV-SV40-Bssk plasmid (Addgene plasmid #1824) that 
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was originally generated in the laboratory of Dr. Philip Leder at Harvard 
Medical School 31. The linear MMTV-FLAG-PADI2 construct was purified and 
microinjected into the pronuclei of fertilized embryos from super-ovulated FVB 
mice, and 2-cell stage embryos were transferred to pseudopregnant mothers. 
The microinjection and embryo transfer was performed by the Stem Cell and 
Transgenics Core at the Cornell University College of Veterinary Medicine. 
Mice were genotyped for the presence of human PADI2 transgene by PCR 
with the primers hPADI2-cds-F/R (see Table 2.1). 
Lentivirus and plasmids for stable FLAG-PADI2 expression in A431 cells 
The human squamous cell carcinoma A431 cell line was obtained from ATCC 
and cultured according to manufacturer’s directions. To generate A431 cells 
overexpressing FLAG-tagged PADI2, two separate plasmids were generated. 
First, for stably transfected A431, FLAG-PADI2 was subcloned (NheI/XhoI) 
from pcDNA3.1-FLAG-PADI2 11 into the pIRES2-EGFP vector (Clontech). This 
vector has bicistronic expression of both FLAG-PADI2 and EGFP by means of 
an internal ribosome entry site (IRES). A431 cells were transfected with 
pIRES2-FLAG-PADI2 using X-tremeGENE 9 (Roche) and stable cells were 
selected in 800 µg/ml G418 for 2-weeks. To generate lentiviral-transduced 
cells, the FLAG-PADI2-IRES-EGFP fragment was excised from the pIRES2-
FLAG-PADI2 plasmid by digestion with MluI and SspI. The linearized fragment 
was blunted with T4 DNA polymerase (NEB), and subcloned into the BamHI-
SalI digested/ T4 blunted pLenti-PGK-GFP-Puro plasmid (Addgene #19070) 
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that was originally generated by Campeau et al. at the University of 
Massachusetts Medical School 32. This plasmid was verified by restriction 
digest and sequencing, and transduction of A431 cells was performed as 
previously described in Campeau et al. using 3rd generation lentiviral 
packaging/envelope vectors (pLP1-pMDLg/pRRE, Addgene #12251; pLP2-
pRSV-Rev, Addgene #12253; and pVSV-G-pMD2.G, Addgene #12259). 
Stably transduced cells were selected in 1 µg/ml puromycin for 2-weeks. 
Mouse skin two-stage carcinogenesis assay 
Two sets of 20 mice each from wild type and PAD2OE groups were selected 
at 6 weeks of age for the carcinogenesis study. We used a well characterized 
two-stage chemical carcinogenesis protocol 33 which included tumor initiation 
by an initial topical application of 10 nm of DMBA (9, 10-dimethyl-1,2-
benzathracene) in 200 µL of acetone to previously shaved dorsal skin. Tumors 
were promoted by twice weekly applications of 1.0 μg of 12-O-
tetradecanoylphorbol-13-acetate (TPA) in 200 μl of acetone beginning 2 
weeks after initiation. The mice were monitored for tumor development, scored 
for number of visible papillomas at the DMBA-TPA application site, and the 
size of papillomas was measured. After 20 weeks of treatment, mice were 
euthanized and the skin lesions were fixed in 4% PFA at 4C for 24 hours, 
paraffin embedded, and sectioned for histopathological evaluation and 
immunostaining.  
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Immunohistochemistry (IHC) and immunofluorescence (IF)  
IHC and IF experiments were carried out using a standard protocol as 
previously described 9.  Primary antibodies are as follows: anti-PADI2 (12110-
1-AP, ProteinTech), anti-FLAG-M2 (F1804, Sigma), anti-Ki67 (ab15580, 
Abcam), anti-phosphoSTAT3 (9131S, Cell signaling) and anti-GFP (ab290, 
Abcam). Sections prepared for IHC were incubated in DAB chromagen 
solution (Vector Laboratories) according to the manufacturer’s protocol, 
washed, and then counterstained with hematoxylin.  The IF slides were 
incubated in streptavidin conjugated-488 (Invitrogen), washed, and then 
mounted using Vectashield containing DAPI (Vector Laboratories).  Negative 
controls for both IHC and IF experiments were either rabbit or mouse IgG 
antibody at the appropriate concentrations. Formalin fixed, paraffin embedded, 
H&E stained tumor sections from transgenic mice were examined for 
histopathological characteristics by a pathologist. 
Western blotting  
Western blotting was carried out as previously described 9. Primary antibodies 
against PADI2 (12110-1-AP, ProteinTech), anti-phosphoSTAT3 (9131S, Cell 
signaling) and FLAG-M2 (F1804, Sigma) were incubated overnight at 4oC. To 
confirm equal protein loading, membranes were stripped and re-probed with 
anti-β-actin (ab8227, Abcam). 
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RNA isolation, semi-quantitative, and quantitative Real-Time PCR (qRT-
PCR) 
RNA was purified using the Qiagen RNAeasy kit, including on-column DNase 
treatment to remove genomic DNA.  The resulting RNA was reverse 
transcribed using the ABI High Capacity RNA-to-cDNA kit according to the 
manufacturer’s protocol (Applied Biosystems).  Semi-quantitative PCR was 
performed using primers (see Table 2.2) for human PADI2 and mouse Padi1, 
Padi2, Padi3, and Padi4, using mouse Gapdh as the loading control. TaqMan 
Gene Expression Assays (ABI) were used to measure relative mRNA levels 
for the transgenic human PADI2 (Hs00247108_m1), along with endogenous 
mouse Padi1 (Mm00478062_m1), Padi2 (Mm00447020_m1), Padi3 
(Mm00478075_m1), and Padi4 (Mm01341658_m1). Mouse Gapdh 
(4352932E) was used as the loading control. In addition, primer sequences for 
gene expression analysis via SYBR-qPCR can be found in Table 2.3 for 
mouse genes, and Table 2.4 for human genes.  Expression levels were 
analyzed using the 2 -ΔΔ C(t) method 34. Data are shown as means ± SD from 
three independent experiments, and were separated using Student’s t-test. 
Assays for cellular malignancy and invasion 
Collagen coated inserts for 24-well plate wells (Falcon BD Fluoroblok; Catalog 
number: 351152, 8 µm pore size) were used to conduct transwell migration 
assays. Briefly, cells were trypsinized into an individual cell suspension, 
washed with DPBS, and added on the coated filters in serum-free DMEM 
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(10,000 cells per filter). The lower chamber of the companion plate (Falcon BD 
Labware) was filled with DMEM supplemented with 10% FBS. At different time 
points (4 and 24 hours) of incubation, the filters were removed for evaluation. 
Cells that had migrated to the other side of the membrane were fixed in 4% 
paraformaldehyde (PFA), and stained with DAPI for visualization of the nuclei. 
The nuclei were counted under fluorescent wide-field microscope. Values for 
cell invasion are expressed as the mean number of cells/20X microscopic field 
over five fields per filter for triplicate experiments. Focus formation assays 
were carried out using stable A431 cells (pIRES2-EGFP-FLAG-PADI2 or 
empty vector control) that were grown in 6-well plates. After 4d, cells were 
fixed with 4% PFA, and stained with crystal violet for subsequent analysis of 
focus formation. After imaging, the crystal violet was removed from the cells 
with 10% acetic acid and absorbance levels were measured (600 nM).  
Histopathology scoring 
Hematoxylin and Eosin (H&E) slides were evaluated by a pathologist (SM), 
who was blinded to the transgenic status of the mice, any clinical history and 
macroscopic features of the tumors. The tumor sections were scored for 
overall inflammatory intensity, cellular EMT features, and local invasion on a 
scale from 0 to 4. The mitotic indexes of the tumors were quantitated as the 
mean value of the number of mitotic figures in 10 randomly selected 400X 
field. The sections were also evaluated for progression of tumors from benign 
papillomas to invasive SCC phenotype as characterized by poorly defined 
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tumor margins, invasive clusters of carcinoma cells extending deep into the 
dermis and subcutis away from the primary tumor site, high desmoplastic 
tissue response, increased degree of anisokaryosis and anisocytosis and 
presence of poorly differentiated carcinoma cells. The scores were statistically 
analyzed for significance by Mann-Whitney-U test and Chi-Square analysis. 
The results were tabulated to show median scores for each histopathologic 
parameter evaluated in WT and transgenic group and the 25%/75% 
interquartile range of scores to show the variation within each group.  
Statistical analysis 
All experiments were independently repeated at least three times unless 
otherwise indicated.  Values were expressed as the mean + the SD. Means 
were separated using Student’s t-test. 
2.4 Results 
Generation of MMTV-FLAG-PADI2 transgenic mice 
To assess the potential role of PADI2 in pithelial carcinogenesis, we generated 
a mouse model in which the human PADI2 gene is overexpressed under 
control of the hormone-responsive MMTV-LTR promoter. The transgenic 
construct consists of a MMTV-LTR promoter placed upstream of the human 
FLAG-tagged PADI2 cDNA, followed by an SV40 splice/polyadenylation site 
(Figure 2.1). MMTV-FLAG-PADI2 mice were generated, and seven potential 
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founders were tested for the presence of transgene by PCR.  We identified 4 
founders (indicated in red, Figure 2.2a), 4807, 4853, 4680, and 4863, that 
carried germline transmission of the FLAG-PADI2 transgene. While founder 
4854 initially appeared to be a low-copy founder line, we failed to see 
transmission of the transgene to subsequent generations at Mendelian ratios, 
perhaps indicating mosaicism. Using semi-quantitative RT-PCR. 
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Figure 2.1: MMTV-FLAG-PADI2 transgenic construct. Schematic of the 
linearized MMTV-FLAG-hPADI2 transgene, containing a FLAG-tagged human 
PADI2 cDNA fragment that was cloned between the EcoRI sites of the MMTV-
SV40-Bssk plasmid 31. The construct used for generation of FLAG-hPADI2-
transgenic mice (also referred to as FLAG-PADI2) consists of FLAG-PADI2 
under the control of the hormone-responsive MMTV-LTR promoter-enhancer 
with an SV40 splice-polyadenylation signal (SV40pA). 
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Figure 2.2: Generation of MMTV-FLAG-PADI2 transgenic mice. (a) PCR 
screening of DNA extracted from mouse tails for the presence of integrated 
human PADI2 transgene (TG – hPADI2). Four founders were identified (red); 
primers for mouse Padi4 were used as a wild-type (WT – mPADI4) control for 
amplification. Primer sequences can be found in Table 2.1. (b) Semi-
quantitative RT-PCR was performed on tissues known to have high 
expression in MMTV-LTR transgenic mice: skin, salivary gland (SG), 
mammary gland (MG), and ovary (note: 4807 founder line was not used due to 
breeding issues and this line was subsequently terminated). Total RNA was 
isolated from tissues and relative mRNA levels for the transgenic human 
PADI2, along with endogenous mouse Padi1, Padi2, Padi3, and Padi4 are 
shown. Mouse Gapdh was used as the loading control. (c) Quantitative RT-
PCR (qPCR) for the human PADI2 transgene was performed across the same 
tissues, using WT skin as the reference, with mouse Gapdh normalization. 
Expression levels were analyzed using the 2 -ΔΔ C(t) method, and data are 
expressed as the mean ± SD from three independent experiments (* p < 0.05). 
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we confirmed the presence of FLAG-PADI2 transcript in the skin, salivary 
gland, mammary gland, and ovary of the transgenic mice (Figure 2.2b). These 
four tissues were chosen for analysis as they have previously been shown to 
have high expression of MMTV-LTR driven transgenes 14. We note that the 
subsequent analysis is for only three founders (4853, 4860, 4863), as founder 
line 4807 had breeding issues and was subsequently terminated. Quantitative 
real-time PCR analysis (qPCR) of these founders for the four same tissues 
was performed; in comparison to other founders, founder 4853 showed the 
highest expression in skin, while founder 4863 had the highest expression in 
salivary and mammary glands (Figure 2.2c). 
 
We first analyzed the mammary glands of the transgenic mice, as we have 
previously established a link between PADI2 and breast cancer. Our initial 
goal was to generate MMTV-driven transgenic mice to investigate the effects 
of ectopic PADI2 overexpression in mammary epithelium in vivo. However, 
while PADI2 transgenic expression in the mammary glands was detected at 
high levels in both virgin (Figure 2.3a) and multiparous mice (Figure 2.3b), we 
failed to detect any gross abnormalities or any observable phenotype in the 
mammary gland of these mice.  
 
PADI2 transgenic mice develop benign and malignant proliferative skin lesions 
While expression from the MMTV-LTR promoter is predominantly localized to 
the mammary and salivary gland, other tissues have been implicated, 
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including the skin and ovaries 13, 14. Surprisingly, we discovered that 20% of 
the mice developed skin lesions after five months (Table 2.2). These lesions 
are macroscopically characterized by abnormalities, such as alopecia, 
multifocal epidermal ulceration often covered in sero-cellular crust, 
hyperkeratosis and thickening of the adjacent epidermis (Figure 2.4a). These 
lesions occur on both the dorsum and ventrum of transgenic mice. We note 
that we have not observed any of these lesions in the wild-type FVB mice, 
indicating that the phenotype is most likely a result of the FLAG-PADI2 
transgene. Histological evaluation of skin lesions by H&E reveals highly 
neoplastic tissue, with features consistent with invasive squamous cell 
carcinoma (SCC). There are nests of neoplastic cells arising from the 
epidermis invading the dermis and subcutis (Figure 2.4b, i). Epidermis 
overlying the neoplasm is extensively ulcerated and the adjacent epidermal 
layers are hyperplastic (Figure 2.4b, i). Keratin pearls characterized by 
concentric layers of keratin embedded within tumor islands are noted which 
are a characteristic feature of SCC (Figure 2.4b, ii and iii). The carcinoma 
cells in the nests and islands of neoplastic cells within the subcutis show high 
degree of anisokaryosis and anisocytosis, with the nuclei often containing 
utliple prominent nucleoli (Figure 2.4b, iv). Clusters of neoplastic cells are 
often surrounded by abundant loose collagenous stroma replacing the dermal 
adnexal structures, consistent with a desmoplastic response (Figure 2.4b, iii 
and iv). Moreover, these skin lesions often contain carcinoma cells that are 
found budding off from the primary neoplasm (Figure 2.4b, iv), indicating the  
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Figure 2.3: MMTV-FLAG-PADI2 expression in the mammary gland.  
(a) Confocal immunofluorescence analysis of FLAG (red) expression in virgin 
mouse mammary gland of a transgenic mouse. The luminal epithelial cells of 
mammary acini strongly express FLAG-PADI2 protein. (b) 
Immunohistochemical staining for PADI2 and FLAG in a multiparous 
mammary gland. The representative image shows a hyperplastic mammary 
gland with acinar epithelial cells strongly expressing both PADI2 and FLAG, 
confirming proper expression of the tagged transgene. 
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Table 2.2: Occurrence of skin lesions in MMTV-FLAG-PAD2 mice 
 
Total n 
 
Mice With Skin 
Lesions (%) 
 
Sex of PAD2OE Mice 
Affected (%) 
PAD2OE Founder 
Line 
Age matched 
WT mice 
 
WT PAD2OE 
 
M F 
PAD2OE-1 17 17 
 
0 58.8 
 
80 20 
PAD2OE-2 20 20 
 
5 20.0 
 
25 75 
PAD2OE-3 47 47 
 
4.4 42.6 
 
55 45 
PAD2OE-4 24 24 
 
4.2 37.5 
 
33 67 
Total n=108 n=108   3.4 39.7   48.3 51.8 
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invasive nature of these tumors. These skin lesions express high levels of 
transgenic PADI2, as immunohistochemical analysis shows PADI2 protein 
expression in the hyperplastic epidermis, neoplastic islands, and in hair 
follicular epithelium (Figure 2.5a, i). In addition, we see high expression of 
PADI2 protein in the neoplastic epithelium surrounding the keratin pearl 
(Figure 2.5a, ii and iii). Furthermore, these tumors are characterized by 
budding nests of carcinoma cells, which invade the adjacent stroma from the 
primary neoplasm. We note that PADI2 protein expression is high in these 
invading clusters of carcinoma cells (Figure 2.5a, iv). Because the PADI2 
antibody can also detect endogenous mouse Padi2, we also evaluated the 
lesions for FLAG-tagged PADI2, and found that we see identical expression 
pattern. FLAG-PADI2 is highly expressed especially within the proliferating 
basal layers of hyperplastic/neoplastic epidermis; thus, suggesting that the 
increased PADI2 expression is a result of the transgene.  
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Figure 2.4: Transgenic FLAG-PADI2 expression in the epidermis of mice 
leads to the development of skin lesions. (a) Representative gross lesion 
showing the skin phenotype, which includes alopecia, multifocal epidermal 
ulceration often covered in a sero-cellular crust, and thickening of the adjacent 
epidermis. (b)  Histological evaluation of the skin sections by H&E reveals 
features consistent with invasive squamous cell carcinoma. (i) Nests of 
neoplastic cells arising from the epidermis are shown invading the deep 
dermis and subcutis, with the epidermis overlying the  neoplasm extensively 
ulcerated. (i) and (ii) Adjacent epidermal layers are hyperplastic with the loss 
of adnexal structures and increase in desmoplastic response (iii). Carcinoma 
cells are often found budding off from the primary neoplasm (iv). 
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Figure 2.5: FLAG-PADI2 expression is high in the skin lesions of 
transgenic mice. (a) Immunohistochemical analysis of FLAG-PADI2 protein 
expression in skin neoplasms from transgenic mice. (i) Lower magnification 
image showing PADI2 protein expression in the hyperplastic epidermis, 
neoplastic islands, and in the hair follicular epithelium. (ii) – (iii) PADI2 protein 
expression in neoplastic cells surrounding concentric layers of keratin (arrow = 
keratin pearl). (iv) Representative image showing high levels of PADI2 protein 
expression in budding nest of carcinoma cells (broken arrow). (b) FLAG 
expression in skin neoplasms from transgenic mice. Scattered clusters of 
neoplastic cells show strong FLAG-tag expression. This staining is especially 
evident in the proliferating basal layers of hyperplastic or neoplastic epidermis. 
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confirmed this using indirect-immunofluorescence to co-stain for FLAG and 
PADI2 expression in the skin lesions of transgenic mice. PADI2 and FLAG 
both co-localize to the neoplastic epithelial cells of a squamous cell carcinoma 
(Figure 2.6, i-iv). While PADI2 shows strong staining in multiple layers of the 
epidermis, we find that FLAG (i.e. transgene) is slightly more restricted to the 
basal layer, which is known to be more stem-cell like and highly proliferative 
35. Interestingly, we also see a slight increase in the proliferative marker, Ki67, 
within the FLAG staining section of the SCC lesion (Figure 2.6b, ii-iv). 
Therefore, this indicates that transgene expression in the skin might lead to an 
increase in proliferation, which is also supported by the identification of a 
subset of these lesions as highly proliferative and invasive SCC. We also note 
that we do not see any expression of the FLAG transgene in normal skin from 
wild-type mice (Figure 2.7, i-vi), as well as very little to any in adjacent normal 
skin from transgenic mice (data not shown). 
 
Transgenic skin lesions have decreased levels of endogenous mouse 
Padis and increased markers of inflammation and EMT 
Since we know that other PADIs can play a role in diseases of the skin, we 
were curious to see what the levels of other PADIs might be in the lesions 
from transgenic mice. Using semi-quantitative RT-PCR, we show human 
PADI2 transgene levels are present as expected in the lesions, as well as 
varying degrees of endogenous mouse Padis (Figure 2.8a). We show by 
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qPCR that representative lesions (2) and (4) have the highest transgene 
expression (Figure 2.8b), and that these two lesions have the highest levels of 
protein expression (lesion 2 = SCC, Figure 2.8c). Surprisingly, we noticed 
what appeared to be a protein-dimer in the western blot that was probed with 
anti-FLAG. Previous evidence has indicated that PADI4 can associate as a 
dimer, and that PADI-activity (i.e. citrullination) is highest in dimerized PADI4 
36. Interestingly, Liu et al. predict that PADI2 also functions as a dimer, as they 
report a high degree of conservation between the two family members, 
especially at the residues important for dimerization 36. We wanted to quantify 
the levels of endogenous mouse Padis by qPCR, and show that in lesions (2) 
and (4), which have the highest levels of human PADI2, also have the lowest 
levels of mouse Padi1, Padi3, and Padi4 (Figure 2.9). There is no observable 
difference reported for endogenous mouse Padi2 levels. To gain better 
perspective as to the potential pathways involved in the progression of MMTV-
FLAG-PADI2 skin lesions, we examined genes known to be involved in 
inflammation and invasion in cancer. We chose these genes based on 
previous reports indicating a role for PADI2 in inflammatory diseases, coupled 
with our report here of the invasive nature of these carcinomas. Interestingly, 
when we examined the two representative lesions with the highest levels of 
transgenic PADI2 (lesions 2 and 4), we found that they have sharply elevated 
levels of Il6 and Il8 (Cxcl15) gene expression (Figure 2.10).  
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Figure 2.6: Confocal immunofluorescence analysis of PADI2, FLAG, and 
Ki67 expression in neoplastic skin lesions of the FLAG-PADI2 transgenic 
mouse.  
(a) Representative image showing co-staining (iv) of FLAG (red, ii) and PADI2 
(green, iii) in the neoplastic epithelial cells of a squamous cell carcinoma from 
a transgenic mouse. Nuclei are stained with DAPI (blue, i). Endogenous Padi2 
shows strong positive staining in 2-3 layers of epidermal cells, while FLAG-
PADI2 is predominantly localized to the basal cell layer. Scattered tumor cell 
islands underlying the epidermis show high levels of PADI2 expression. (b) 
Representative image showing co-staining (iv) of the proliferative marker, 
FLAG (red, ii), and Ki67 (green, iii) in neoplastic epithelial cells of squamous 
cell carcinoma. Tumor islands that are strongly positive for FLAG-PADI2 
expression levels contain an increased number of Ki67 positive cells (iv). 
Nuclei are stained with DAPI (blue, i) 
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Figure 2.7: Normal skin section from wild-type mice as a negative control 
for FLAG staining. (a) Representative image showing co-staining (vi) of 
FLAG (red, iii) and Ki67 (green, iv) in normal skin sections from a wild-type 
(WT) mouse. Bright-field image (ii and v). Both FLAG-tag and PADI2 protein 
expression are absent, concomitant with reduced Ki67 levels. Nuclei are 
stained with DAPI (blue, i)  
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Figure 2.8: Transgene expression in the skin lesions of MMTV-FLAG-
PAD2 mice. (a) Semi-quantitative RT-PCR on four representative skin lesions 
from transgenic mice (Lesions 1-4). Total RNA was isolated from lesions and 
normal wild-type skin, and relative mRNA levels for the transgenic human 
PADI2, along with endogenous mouse Padi1, Padi2, Padi3, and Padi4 are 
shown. Mouse Gapdh was used as the loading control. (b) Quantitative RT-
PCR (TaqMan) for the human PADI2 transgene was performed across the 
same lesions, using normal WT skin as the reference, along with mouse 
Gapdh normalization. Expression levels were analyzed using the 2 -ΔΔ C(t) 
method, and data are expressed as the mean ± SD from three independent 
experiments (* p < 0.05). (c) Representative western blot for skin from WT and 
transgenic (TG) mice, along with lesions (3) and (4), as well as (2), which is 
noted as a SCC skin tumor. Whole-cell lysates were probed for FLAG 
expression, with a predicted protein size of ~75 kDa (note the presence of a 
suspected homodimer at 150 kDa). β-actin was used as a loading control. 
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Furthermore, these two lesions also display markers of EMT, as E-cadherin is 
decreased, along with a concomitant increase in vimentin (Vim) and the E-
cadherin repressor, Snai1 (Figure 2.10). 
 
Overexpression of PADI2 in human squamous cell carcinoma A431 cells 
increases invasiveness and malignancy 
Transgenic MMTV-FLAG-PADI2 mice show that ectopic expression of PADI2 
is sufficient to drive tumorigenesis in epithelial cells and that this expression 
correlates with an increase in markers of invasion and EMT. We wanted to see 
if could replicate these results in a human skin cancer cell line, A431. The 
A431 cell line is a human squamous carcinoma cell line that was isolated from 
a vulva epidermoid carcinoma. To test the oncogenic potential of PADI2 in this 
cell line, we first transiently expressed FLAG-PADI2 using standard plasmids 
for mammalian protein expression  
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Figure 2.9: Lesions from MMTV-FLAG-PADI2 transgenic mice that 
express the highest levels of human PADI2, have decreased mouse 
Padi1, Padi3, and Padi4. Total RNA from transgenic skin lesions (1-4) and 
normal wild-type skin was isolated and reverse transcribed to cDNA. The 
relative mRNA levels for human transgenic PADI2, along with mouse Padi1, 
Padi2, Padi3, and Padi4, were determined by qPCR (TaqMan) using normal 
WT skin as the reference, along with Gapdh normalization. Expression levels 
were analyzed using the 2 -ΔΔ C(t) method, and data are expressed as the mean 
± SD from three independent experiments (* p < 0.05). 
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Figure 2.10: Skin lesions from MMTV-FLAG-PADI2 transgenic mice 
express markers of inflammation and EMT. Total RNA from transgenic skin 
lesions (1-4), along with transgenic and wild-type (WT) skin, was isolated and 
reverse transcribed to cDNA. Relative mRNA levels for the representative 
genes (see Table 4.3 for gene list and primer sequences) were determined by 
qPCR (SYBR) using normal WT skin as the reference, along with β-actin 
(Actb) normalization. Expression levels were analyzed using the 2 -ΔΔ C(t) 
method, and data are expressed as the mean ± SD from three independent 
experiments (* p < 0.05).  
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(pcDNA3.1-FLAG-PADI2) and (pIRES2-FLAG-PADI2) and associated empty 
vectors. We found that in both of the cell lines expressing high levels of FLAG-
PADI2 (Figure 2.11a and b), E-cadherin protein levels were reduced when 
compared to the empty vector control cells (Figure 2.11a). In addition, we see 
a concomitant increase in vimentin in these two cell lines. We examined the 
FLAG-PADI2 overexpressing A431 cells for expression of genes involved in 
inflammation and EMT, and found the results were similar to those seen in the 
transgenic mice. Both IL6 and IL8 gene levels are increased, while we see a 
reduction in E-cadherin, along with concomitant increases in SNAIL and SLUG 
(Figure 2.11b).  
 Given the data from our transiently transfected A431 cells, along with 
our data from the transgenic mice, we decided to test whether stable 
overexpression of FLAG-PADI2 might have an effect on the cellular 
malignancy and/or invasiveness of A431 cells. Using both lentiviral 
transduction of FLAG-PADI2, and traditional transfection, we created two 
stable cell lines overexpressing various levels of PADI2. The lentiviral 
generated stable cell line (pLenti-FLAG-PADI2) is under the control of the 
phosphoglycerate kinase (PGK) promoter, which is weaker than the 
cytomegalovirus promoter used in the pIRES2-FLAG-PADI2 stably transfected 
cells. After selecting for 2-3 weeks, we assayed for PADI2 levels, showing, as 
expected, that pLenti-FLAG-PADI2 (pLenti-FP2) had slightly less expression 
of PADI2 than pIRES2-FLAG-PADI2 (pIRES-FP2) (Figure 2.12a). Next, we 
tested the invasive properties of these cell lines by measuring their ability to 
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migrate through a collagen matrix. For both cell lines, we see a significant 
increase in cellular migration after 24h, while the pIRES2-FP2 cell line also 
has a significant increase after 4h (Figure 2.12b). These results suggest that 
PADI2 dosage might correlate with invasion. Recent evidence from our lab 
suggests that PADI2 can be expressed in the nucleus, as well as the 
cytoplasm 10; therefore, we decided to analyze the localization of PADI2 in 
vitro using indirect- immunofluorescence and confocal microscopy. 
Interestingly, we show that FLAG-PADI2 expression is predominantly nuclear 
in the stable A431-pIRES-FP2 cells (Figure 2.13b) compared to empty vector 
control cells (Figure 2.13a). Both the pLenti-FP2 and pIRES2-FP2 plasmids 
express GFP bicistronically via an internal ribosome entry site (IRES); 
therefore, we show that GFP in the pIRES2-FP2 stable cells is predominantly 
cytoplasmic (Figure 2.13a, iii; and b, iii), indicating different localization of the 
two overexpressed proteins (FLAG-PADI2 and GFP). Finally, we wanted to 
test the stable A431-pIRES2-FP2 cells for any increase in cellular malignancy. 
Assaying for focus formation, we show a significant increase in the FLAG-
PADI2 overexpressing A431 cells compared to the empty vector control 
(Figure 2.14a). In addition, we show that the morphology of these cells also 
displays an elongated, fibroblast-like shape, indicative of cells that have 
undergone EMT (Figure 2.14b).  
 
 
 
 53 
 
 
 
 
 
Figure 2.11: Transient overexpression of FLAG-PADI2 increases markers 
of inflammation and EMT in the human squamous cell carcinoma A431 
cell line.  
(a) Human squamous cell carcinoma cells, A431, were transiently transfected 
with FLAG-PADI2 (pcDNA3.1-FP2 or pIRES2-FP2) or empty vector 
(pcDNA3.1-emtpy). Western blot analysis of protein expression for EMT 
markers, E-cadherin and vimentin, along with PADI2, was performed on 
transfected A431 cells. β-actin was used as a loading control. Total RNA was 
isolated and relative PADI2 levels for the FLAG-PADI2 transfected A431 cells, 
relative to empty vector control (ACTB normalized), were analyzed by qPCR 
(SYBR). Additional genes were also analyzed, see Table 2.4 for full gene list 
and primer sequences. Expression levels were analyzed using the 2 -ΔΔ C(t) 
method, and data are expressed as the mean ± SD from three independent 
experiments (* p < 0.05).  
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Figure 2.12: A431 cells stably overexpressing PADI2 have increased 
invasion through a collagen matrix. (a) A431 cells were stably transfected 
with pIRES2-FLAG-PADI2 (pIRES2-FP2) or infected with lentivirus expressing 
FLAG-PADI2-EGFP (pLenti-FP2). Control vectors only express the EGFP 
gene (pIRES2-GFP and pLenti-GFP). Western blot analysis for PADI2 protein 
expression levels, β-actin was used as a loading control. Total RNA was 
isolated and relative PADI2 levels for the FLAG-PADI2 transfected A431 cells, 
relative to GFP vector control (ACTB normalized), were analyzed by qPCR 
(SYBR). Expression levels were analyzed using the 2 -ΔΔ C(t) method, and data 
are expressed as the mean ± SD from three independent experiments (* p < 
0.05). (b) Transwell migration assay through a collagen matrix – cells were 
seeded and allowed to migrate through a collagen matrix. After 4h or 24h, 
cells that migrated were counted under a microscope at 40X magnification.  
Data are expressed as the mean ± SD from three independent experiments (* 
p < 0.05). 
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Figure 2.13: Co-localization of FLAG and GFP in A431 cells stably 
overexpressing FLAG-PADI2. (a) Confocal immunofluorescence analysis of 
the co-localization (iv) of FLAG (red, ii) and GFP (iii) in the nucleus and 
cytoplasm of A431 cells expressing the empty vector (pIRES2-GFP) or the 
FLAG-PADI2 expressing vector (b), which has bicistronic expression of both 
PADI2 and EGFP (pIRES2-GFP-FLAG-PADI2). Note the nuclear expression 
of FLAG (PADI2). Nuclei are stained with DAPI (blue, i). 
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Figure 2.14: A431 skin cancer cells overexpressing FLAG-PADI2 show 
increased malignancy and EMT morphology. (a) Cells stably 
overexpressing FLAG-PADI2 (A431-FP2), or EGFP control (A431-GFP), were 
grown for 4d in a 6-well plate, fixed with 4% PFA, and stained with crystal 
violet for subsequent analysis of focus formation. After imaging, the crystal 
violet was removed from the cells with 10% acetic acid and absorbance levels 
were measured (600 nM). Data are expressed as the mean ± SD from three 
independent experiments (* p < 0.05). (b) Representative morphology of A431 
cells overexpressing FLAG-PADI2, showing elongated cells with fibroblast-like 
shape, indicative of cells that have undergone EMT. 
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MMTV-FLAG-hPAD2 mice form larger skin tumors 
Control and transgenic mice were treated with both DMBA and TPA and 
monitored for the development of skin tumors such as papillomas and 
carcinomas. The  transgenic mice developed increased number of papillomas 
and these tumors  grew at a faster rate (Figure 2.15A and 2.15B). The 
increased frequency of papilloma formation in the transgenic mice was 
especially evident in the earlier weeks of the study. The tumor sections were 
immunostained for the FLAG-hPAD2 expression and the MMTV-FLAG-hPAD2 
tumors showed positive staining for FLAG-PAD2, confirming that the 
transgene is being translated in the DMBA-TPA induced tumor cells (Figure 
2.16). The WT tumor tissue showed only minimal background staining for 
FLAG.  
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Figure 2.15: The incidence and growth of skin papillomas in DMBA-TPA 
treated mice. DMBA treated mice were further treated with TPA twice weekly 
and monitored for the number of papillomas developed and the size of each 
papilloma. The average of number of papillomas in both wild type (WT) and 
MMTV-FLAG-hPAD2 (TG) group were plotted in Figure 3.2A (mean + SEM, * 
p value <0.05). Average size of the largest papilloma plotted against week of 
TPA treatment is shown in Figure 3.2B (mean + SEM). MMTV-hPAD2 mice 
show statistically significant increase in the number of papillomas and these 
tumors tend to be of larger size.   
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Figure 2.16: Anti-FLAG immunostaining and confocal imaging to detect 
transgenic expression of hPAD2 in skin tumors. Formalin fixed, paraffin 
embedded tumor sections were stained with anti-FLAG antibody and imaged 
using a confocal microscope for the expression of FLAG-hPAD2 in tumor cells 
(Red). There is strong staining for FLAG-hPAD2 in the transgenic tumor 
sections while the WT tumor tissue show minimal background staining 
(measurement bar = 200µm).  
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PAD2OE tumors show increased inflammation and invasiveness 
The histopathological examination confirmed that the DMBA-TPA tumors in 
treated mice ranged from epidermal hyperplasia, benign papillomas to 
invasive squamous cell carcinomas (Figure 2.17A). Histopathological 
examination of the tumor sections from WT and transgenic mice showed that 
the tumors carrying hPAD2 transgene contained significantly higher levels of 
inflammatory cell infiltrate compared to the WT tumors (Figure 2.17B). WT 
tumors mostly were benign papillomas with hyperkeratosis, numerous 
invaginations, and intact basement membrane limiting the tumor cells. 
Approximately in 80 percent of the transgenic mice, the tumors developed into 
squamous cell carcinoma with invasive features such as breaching of the 
basement membrane, poorly defined tumor borders, high degree of anaplasia 
and local or regional lymph node metastasis (Figure 2.18A). Blinded 
histopathology scores were analyzed by Mann-Whitney-U test and Chi-sqyare 
analysis and there were significant differences between transgenic and WT 
tumors with respect to tissue characteristics such as intensity of inflammation, 
EMT cellular features, mitotic index, and invasiveness (Figure 2.18B and 
Table 2.5). The median score values are plotted in Figure 2.18B, which 
represent the intense inflammatory component observed within the transgenic 
tumors. The inflammatory cells are predominantly neutrophils, often forming 
inflammatory cell islands embedded within clusters of papilloma and 
carcinoma cells.   
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Figure 2.17: Histopathological evaluation of DMBA-TPA induced skin 
tumors in WT and MMTV-FLAG-hPAD2 mice. Figure 3.4A shows that 
following DMBA-TPA treatment, mice developed skin lesions varying in their 
histopathologic properties and invasiveness ranging from 
hyperplasia/dysplasia, benign papillomas to invasive squamous cell 
carcinomas. In comparison to the WT tumors, the transgenic tumors contained 
increased areas of tumor associated inflammation consisting of infiltrating 
immune cells.  
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Figure 2.18: Histopathological scoring of DMBA-TPA induced tumors for 
inflammation and invasiveness. The tumors were classified into benign 
papillomas and invasive SCC based on histopathological features and the 
percentage of mice with papillomas and mice with both papillomas and SCC 
were plotted. A significantly higher percentage of the transgenic mice 
developed invasive SCC compared to the WT mice which developed 
predominantly benign papillomas (Figure 3.5A). The median scores for 
histopathology parameters are plotted in Figure 3.5B and table 3.2 based on 
the pathologist’s blinded evaluation of 17 different cases in each group. 
Transgenic tumors received a higher score for inflammation, invasion, EMT 
cellular morphological features and mitotic index compared to the WT tumors. 
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Table 2.5: Chi-square (X2) analysis of histopathology scoring of DMBA-
TPA induced tumors. H&E sections from WT and transgenic tumors were 
scored for histopathological features by a pathologist blinded to the genotype 
of the mice. The tumors scored on a scale of 0 to 4 for inflammation, invasion 
and EMT morphology. Mitotic index was calculated as the average of total of 
mitotic figures observed in 10 randomly selected 400X microscopic field. The 
results were analyzed by Mann-Whitney-U test and Chi-square analysis and 
the results are given as the median score for each group, 25%/75% 
interquartile range, X2 values and the corresponding p-values. The transgenic 
tumors received significantly higher scores for these four histopathologic 
parameters of inflammation, invasion and cell proliferation compared to the 
WT tumors.  
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Figure 2.19: Lymph node metastasis of SCC in a MMTV-FLAG-hPAD2 
mice.  
A H&E stained section of axillary lymph node (LN) from a MMTV-FLAG-
hPAD2 mice showing regional LN metastasis of SCC. An unaffected control 
LN image from the WT mice is shown to the left. The SCC metastatic focus is 
composed of sheet of carcinoma cells with poorly defined borders, no 
basement membrane and with a central core of inflammatory cells 
predominantly neutrophils. 
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Figure 2.19 shows an example of focal regional lymph node metastasis of  
SCC cells in a MMTV-FLAG-hPAD2 mouse. Interestingly, the core of this  
microinvasive focus of tumor cells harbors a cluster of immune cells, 
predominantly neutrophils, suggesting that the tumor cells favor recruitment of 
immune cells potentially by regulating cytokine secretion. The mRNA 
expression of inflammatory cytokines such as IL6, mouse IL8 homologues 
(LIX, MIP2), and Vimentin were elevated in the transgenic tumors while the 
cell adhesion marker E-cadherin mRNA was reduced. This finding was in 
consistent with the histopathological pattern of neutrophil rich inflammation in 
these transgenic tumors which may be regulated by LIX and MIP2 levels. A 
correlation analysis between transgene mRNA expression and these 
inflammatory and EMT markers showed that hPAD2 mRNA levels are highly 
positively correlated with inflammatory cytokine levels (MIP2 and LIX) and 
vimentin while showing a strong negative correlation with E-cadherin mRNA 
levels (Figure 2.20). This suggested that potentially hPAD2 transgene 
overexpression may be affecting the transcription of various inflammatory and 
cell adhesion markers in the tumor cells thus regulating the tumor 
microenvironment and tumor cell migration.  
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Figure 2.20: Inflammatory cytokine expression and EMT markers in 
DMBA-TPA induced skin tumors in WT and MMTV-FLAG-hPAD2 mice. 
The DMBA-TPA induced skin tumors were collected in RNA-later at the end of 
the study, extracted RNA and qRT-PCR was performed. Figure 3.7A shows 
that IFNγ, CCL17 and IL8 homologues MIP2 and LIX are elevated in 
transgenic tumors compared to WT tumors. The correlation coefficients of 
inflammatory markers (MIP2, LIX) and EMT markers (Vimentin, E-cadherin 
and Snail) to the transgene hPAD2 levels and is given in Figure 3.7B. The 
inflammatory cytokines and EMT marker vimentin and the E-cadherin 
repressor, Snail showed strong positive correlation with the hPAD2 levels 
while the cell adhesion marker E-cadherin showed a strong negative 
correlation.  
 
 75 
 
 
 
 
 
 76 
 
MMTV-FLAG-hPAD2 mice skin tumors show increased CCL7 expression 
and activation of STAT3 pathway 
 
We observed that the IL8 mouse homologues MIP2, LIX and IL6 mRNA levels 
were highly elevated in PAD2 overexpressing tumors. This result is consistent 
with the results we previously observed in the lab using a PAD2 
overexpressing human SCC cell line 37 and the pattern observed in the 
spontaneous skin tumors in these transgenic mice. One of the known 
downstream pathways activated by IL8 and IL6 receptor activation is the 
STAT3 pathway. Given the high levels of IL6 present in the transgenic tumor 
cells, we predicted that these tumor cells will also contain increased levels of 
nuclear phospho-STAT3 in higher frequency. Immunofluorescence staining 
using anti-phospho-STAT3 antibody and confocal microscopic imaging 
showed that nuclear localization of phospho-STAT3 is significantly increased 
in the transgenic tumors (Figure 2.21). Activation of phospho-STAT3 has 
been shown to assist in tumor progression and can lead to anti-apoptotic 
effects in tumor cells. 
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Figure 2.21: phosho-STAT3 levels in DMBA-TPA induced skin tumors in 
WT and MMTV-FLAG-hPAD2 mice. Formalin fixed, paraffin embedded tumor 
sections were stained with anti-phospho-STAT3 antibody and imaged using a 
confocal microscope to detect levels and nuclear localization of phosphor-
STAT3 (Red). There was strong nuclear staining for phosphor-STAT3 in the 
transgenic tumor sections while the WT tumor tissue showed reduced nuclear 
staining (measurement bar = 200µm). 
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2.5 Discussion 
In the present study, we have demonstrated that transgenic mice 
overexpressing PADI2 in the epidermis are sufficient to develop skin lesions 
that progress to invasive squamous cell carcinomas (SCC). Moreover, we 
have verified these results using the human squamous cell carcinoma cell line, 
A431, in which we stably overexpressed PADI2, resulting in the increased 
invasiveness and malignancy of these cells.  
While PADI2 transgenic expression in the mammary glands was 
detected, the MMTV-FLAG-PADI2 mice failed to develop any mammary 
tumors. Transgenic mice under control of the MMTV-LTR promoter can often 
have low expression in the mammary gland, or only noticeable expression in 
the mammary glands of lactating or multi-parous mice 38-40. In addition, the 
MMTV promoter often becomes hypermethylated, and thus silenced 41. While 
we have noted high expression in the mammary glands of our transgenic 
mice, perhaps further analysis of transgenic PADI2 expression over the life 
span of the mice might indicate age-related variation in expression. Future 
studies will examine the effectiveness of challenging our MMTV-FLAG-PADI2 
mice, either genetically or chemically, to induce mammary carcinomas. 
Recent research has shown that inflammation plays an important role in 
the development of advanced SCC tumors in mice 42. As mentioned 
previously, numerous studies have documented a role for PADI-mediated 
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citrullination in immune diseases characterized by inflammation. In addition, 
we recently identified a new role for PADI2 in inflammation, as we found that 
PADI2-mediated histone tail hypercitrullination is important during macrophage 
extracellular trap (MET) formation in inflamed tissues 43, 44.  Increasing 
evidence supports a pro-tumorigenic role for immune cells and inflammatory 
processes, with tumor-promoting inflammation recently defined as an 
emerging hallmark of cancer 45, 46. Many inflammatory mediators, including 
cytokines and chemokines, are important for the growth and proliferation of 
pre-malignant cells 47. These mediators often activate oncogenic transcription 
factors, such as NFκB and STAT3 48-50. PADI2 has been shown to regulate 
cytokine signaling in macrophages via citrullination of IKKγ, which controls 
NFκB expression activity 51. Furthermore, PADI2 has also been shown to 
citrullinate CXCL8 (IL8) 52, again suggesting a role for regulating the 
inflammatory microenvironment of the cancer microenvironment.  
We show here that Il6 and Il8 expression is increased in the skin 
lesions of MMTV-FLAG-PADI2 transgenic mice. These results were also 
confirmed using the A431 cell line overexpressing FLAG-PADI2. Both IL6 and 
IL8 have been shown to be important in the progression of cancer, having a 
critical role in tumor growth, angiogenesis, and EMT 53-62. Further work is 
needed to identify exactly how PADI2 regulates the expression of these two 
inflammatory mediators. 
In addition to increased Il6 and Il8 expression, skin lesions in the 
MMTV-FLAG-PADI2 mice also display increased markers of invasiveness and 
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EMT. Furthermore, the A431 cells overexpressing FLAG-PADI2 show 
increased invasion through a collagen matrix when compared to control 
transfected cells. Cells undergoing EMT are often at the leading edge of 
invasive tumors that are epithelial in origin. EMT is an important process 
during normal development by which epithelial cells acquire mesenchymal, 
fibroblast-like properties, and show reduced intercellular adhesion and 
increased motility. Several oncogenic pathways have been implicated in EMT, 
including Src, Ras, Ets, Wnt/β-catenin, as well as signaling downstream from 
the PI3K-AKT-axis resulting from IGF1, TGFβ, EGFR, and HER2 activation 63, 
64. Recently, studies have suggested a variety of epigenetic mechanisms may 
also play a role in EMT 65. Interestingly, we have recently reported on a role 
for PADI4 in the progression of breast cancer and EMT, via the citrullination of 
GSK3β, which is known to regulate TGFβ 66. Stadler et al. establish that 
PADI4 serves as a tumor suppressor, with dysregulation of PADI4-mediated 
citrullination of nuclear GSKβ activating TGFβ signaling, thereby inducing EMT 
in breast cancer cells and the production of more invasive tumors in vivo. 
Interestingly, the two representative skin lesions from MMTV-FLAG-PADI2 
mice, which express the highest levels of transgenic PADI2, have markedly 
reduced levels of endogenous Padi4. Perhaps this indicates cross-talk 
between PADI2 and Padi4, working in opposite fashion to promote 
tumorigenesis and invasiveness in tumors. Nevertheless, the critical molecular 
feature of EMT is the downregulation of E-cadherin, a cell adhesion molecule 
present in the plasma membrane of most normal epithelial cells. This is the 
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earliest event in EMT; however, as the cell progresses from epithelial-like to 
mesenchymal-like cells, they are often accompanied by the increased 
expression of Snail1 (Snai1) and the intermediate filament vimentin. We show 
here that Snail1 is upregulated in the skin lesions of MMTV-FLAG-PADI2 
mice, E-cadherin is reduced, and that vimentin levels increase, all indicative of 
EMT. This molecular evidence matches well with the invasive histology of the 
lesions, as we report that a subset of lesions advance to highly invasive 
squamous cell carcinomas. Snail expression is inversely correlated with E-
cadherin expression, and has been shown to bind to E-boxes in the promoter 
of E-cadherin, directly repressing gene expression via various mechanisms 67, 
68. The most established method of repression is via the recruitment of HDAC 
containing complexes to the E-cadherin promoter, such as the 
Sin3A/HDAC1/HDAC2 complex 69. We have already shown that PADI2 can 
function as an epigenetic regulator of genes in breast cancer cells 11; however, 
further work is needed to characterize the mechanism behind PADI2 
regulation of genes involved in both inflammation and EMT.  
2.6 Conclusions 
These tumors express high levels of transgenic human PADI2 and display 
markers of increased invasiveness (i.e. EMT). Furthermore, a subset of these 
tumors shows the hallmarks of malignant progression  from skin lesions to 
highly invasive squamous cell carcinomas. We have also replicated these 
results in the human squamous cell carcinoma cell line, A431. Using a two 
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stage chemical carcinogenesis model, in this study we show that MMTV-
FLAG-hPAD2 mice are susceptible to skin tumor formation and in the 
presence of the transgene. These tumors often develop into invasive SCC and 
tend to increased more tumor associated inflammation. The cytokine profile 
between WT and transgenic tumors also showed a striking contrast with the 
transgenic tumors expressing more IL8 homologues (MIP2 and LIX), CCL17 
and IL6. Furthermore, we found that STAT3 pathway is activated in the 
transgenic tumors as evidenced by increased nuclear localization of phosphor-
STAT3, which is consistent with the effect of IL8 and IL6 receptor activated 
downstream signaling. We also showed that PAD2 levels are inversely 
correlated with cell adhesion marker E-cadherin and favor the EMT transition 
by increasing Snail expression, which is an E-cadherin repressor. This study 
provides novel insight into the role of PAD2 in tumor progression, regulation of 
invasive properties, and tumor associated inflammation and cytokine 
expression by tumor cells. Collectively, these studies provide functional and 
mechanistic evidence establishing PADI2 as a potential novel oncogene in the 
progression of epidermal carcinomas (Figure 2.22).  
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Figure 2.22: The role of PAD2 overexpression in regulation of tumor 
invasion and inflammation. hPAD2 transgene overexpression in DMBA-TPA 
induced skin tumors play critical role in regulating tumor associated 
inflammation and tumor invasiveness. Cytokines such as IL8 homologues 
MIP2 and LIX and IL6 can activate STAT3 pathway which in turn regulate 
antiapoptotic marker expression and tumor cell proliferation. Elevated levels of 
CCL17 in the transgenic tumors contribute to lymphocyte recruitment to the 
tumor microenvironment. PAD2 overexpressing tumors show EMT 
characteristics compared to the WT tumors making them more invasive. A 
positive feedback loop may exist between paracrine signaling of IL8 and IL6 
activation of tumor cells and enhanced secretion of cytokines by these tumor 
cells which further favor immune cell recruitment. 
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Table 2.1: Primers for Semi-quantitative RT-PCR 
 
   Primer Name Sequence Amplicon 
mPADI4-gDNA-F CCCACCCTGTGTGAGTTCTT 395bp 
mPADI4-gDNA-R GCCCAGAGCTTCATGTCTTC 
 hPADI2-cds-F ATTGAGATCTCCCTGGATGTG 194bp 
hPADI2-cds-R TCCTTGAGATCTTCCTTGCTG 
 mPADI1-cds-F CGTCTATAGTGATGTGCCCA 219bp 
mPADI1-cds-R CTCCTGTGACTCAAAGTATGAC 
 mPADI2-cds-F CAAGATCCTGTCCAATGAGAG 189bp 
mPADI2-cds-R ATCATGTTCACCATGTTAGGGA 
 mPADI3-cds-F GATTCTTAACAACCAGAGCCT 183bp 
mPADI3-cds-R CAGCATATTCACCAAGTCGG 
 mPADI4-cds-F CTACTCTGACCAAGAAAGCC 193bp 
mPADI4-cds-R ATTTGGACCCATAACTCGCT 
 mGAPDH-cds-F GGGCATCTTGGGCTACAC 209bp 
mGAPDH-cds-R GGTCCAGGGTTTCTTACTCC 
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Table 2.3: Primers for mouse quantitative RT-PCR (SYBR) 
  Primer Name Sequence 
mECAD-F ATCCTCGCCCTGCTGATT 
mECAD-R ACCACCGTTCTCCTCCGTA 
mVIM-F TGCGCCAGCAGTATGAAA 
mVIM-R GCCTCAGAGAGGTCAGCAAA 
mSNAIL-F CTTGTGTCTGCACGACCTGT 
mSNAIL-R CAGGAGAATGGCTTCTCACC 
mCOX2-F GATGCTCTTCCGAGCTGTG 
mCOX2-R GGATTGGAACAGCAAGGATTT 
mGSK3B-F TCCTTATCCCTCCACATGCT 
mGSK3B-R CCACGGTCTCCAGCATTAGT 
mIL6-F GCTACCAAACTGGATATAATCAGGA 
mIL6-R CCAGGTAGCTATGGTACTCCAGAA 
mIL8-F TGCTCAAGGCTGGTCCAT 
mIL8-R GACATCGTAGCTCTTGAGTGTCA 
mKI67-F CAAGAGGAAGTCTCTTGGCACT 
mKI67-R ACTCTTGTTTCCCTGGAGACTG 
mPADI1-F ATGACCCCCAACACTCAGC 
mPADI1-R CGGCCGTGGATATCTGTC 
mPADI2-F GATCCTCATCGGAAGCAGTT 
mPADI2-R AGTCGCGTACCACCTTGG 
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mPADI3-F CCCCTAGCAATGACCTCAAC 
mPADI3-R ATAGGCCAGGGGCAAATG 
mPADI4-F TGACCCTACAGGTGAAAGCA 
mPADI4-R GGGTCCATAGTATGAAACTCGAA 
mACTB-F CTAAGGCCAACCGTGAAAAG 
mACTB-R ACCAGAGGCATACAGGGACA 
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Table 2.4: Primers for human quantitative RT-PCR (SYBR) 
  Primer Name Sequence 
hPADI2-F TCTCAGGCCTGGTCTCCAT 
hPADI2-R AAGATGGGAGTCAGGGGAAT 
hECAD-F TGGAGGAATTCTTGCTTTGC 
hECAD-R CGCTCTCCTCCGAAGAAAC 
hVIM-F GGCTCGTCACCTTCGTGAAT 
hVIM-R GAGAAATCCTGCTCTCCTCGC 
hGSK3β-F GACATTTCACCTCAGGAGTGC 
hGSK3β-R GTTAGTCGGGCAGTTGGTGT 
hSNAIL-F GCTGCAGGACTCTAATCCAGA 
hSNAIL-R ATCTCCGGAGGTGGGATG 
hSLUG-F TGGTTGCTTCAAGGACACAT 
hSLUG-R GCAAATGCTCTGTTGCAGTG 
hNFκB-F CTGGCAGCTCTTCTCAAAGC 
hNFκB-R TCCAGGTCATAGAGAGGCTCA 
hRELA-F ACCGCTGCATCCACAGTT 
hRELA-R GATGCGCTGACTGATAGCC 
hCOX2-F GCTTTATGCTGAAGCCCTATGA 
hCOX2-R TCCAACTCTGCAGACATTTCC 
hIL6-F GCCCTGAGAAAGGAGACATGTAA 
hIL6-R TTGTTTTCTGCCAGTGCCTC 
   90 
hIL8-F ACTGAGAGTGATTGAGAGTGGAC 
hIL8-R AACCCTCTGCACCCAGTTTTC 
hCCND1-F GAAGATCGTCGCCACCTG 
hCCND1-R GACCTCCTCCTCGCACTTCT 
hKI67-F TTACAAGACTCGGTCCCTGAA 
hKI67-R TTGCTGTTCTGCCTCAGTCTT 
hMYC-F CACCAGCAGCGACTCTGA 
hMYC-R GATCCAGACTCTGACCTTTTGC 
hHRAS-F GGACGAATACGACCCCACTAT 
hHRAS-R TGTCCAACAGGCACGTCTC 
hACTB-F CCAACCGCGAGAAGATGA 
hACTB-R CCAGAGGCGTACAGGGATAG 
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3.1 Abstract 
Histone citrullination mediated by peptidylarginine deiminases (PAD) is known 
to play a critical role during neutrophil extracellular trap release (“ETosis”). We 
previously have shown that site specific histone citrullination marks such as 
Histone H4 Citrulline 3 (H4Cit3) are abundantly present in the extracellular 
chromatin released during the process of ETosis by neutrophils. Following the 
observation that macrophages express high levels of the PAD isozyme, PAD2, 
we wanted to see if hypercitrullination is mediated by PAD2 in macrophage 
extracellular trap release (METs). In the present study, using RAW264.7 and 
primary peritoneal macrophages, we show that PAD2 is involved in ET release 
and that PAD2 deletion and drug-mediated PAD inhibition in macrophages 
affect the ability of macrophages to release extracellular chromatin traps 
following chemical stimulation by phorbol myristate acetate (PMA). 
Additionally, the morphological characteristics of METs were affected in the 
absence of nuclear PAD2. In order to study the in vivo significance of METs in 
human diseases, we have also characterized the presence of METs in human 
tongue squamous cell carcinomas (tSCC). Macrophages form a predominant 
inflammatory component within the tumor associated microenvironment of 
various carcinomas and sarcomas. The tSCC tissue sections contain tumor 
associated macrophages (TAMs) that are strongly positive for nuclear and 
cytoplasmic PAD2 expression. Immunostaining and confocal microscopic 
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evaluation of the tumor tissue showed scattered clusters of TAM-associated 
ETs that were stained positively for both DNA and high levels of citrullinated 
histones. Our study strongly suggests that PAD2 is involved in MET release 
and that PAD2 mediated MET release is an important process regulating 
inflammatory microenvironment in human carcinomas such as tSCC. 
3.2 Introduction 
Neutrophils can undergo a novel cell death mechanism called Neutrophil 
Extracellular Trap release (NETosis) following stimulation by pathogens or 
chemical treatments (LPS, PMA, IFN I and II, IL8) even though the exact 
induction process is not yet well described 1. NETs are known to be composed 
of nuclear constituents such as chromatin DNA and histones in which various 
peptides and enzymes (e.g. elastase and myeloperoxidase) are embedded. A 
study by Brinkmann, Reichard 2 have characterized the process of NETosis 
and several initial studies had focused on the role of NETs in infectious 
diseases such as pneumococcal pneumonia, mastitis, streptococcal fasciitis 
and appendicitis. Brinkmann et al (2004) also showed, using electron 
microscopy, that NETs are composed of fibrous DNA strands with a diameter 
ranging from 15-17 nm and globular protein domains of various size 
aggregating to the DNA. It is also important to point out that the maturation of 
neutrophils is an important factor for their ability to release NETs as described 
by Martinelli et al. Using a microarray approach, Martinelli et al found that fully 
differentiated neutrophils highly express interferon target genes and that 
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interferon treatment can prime neutrophils for faster release of NETs. 
However, no priming steps were needed to induce NETs by stimulation with 
PMA, LPS or IL8. More recent studies focus on the broader role of ETosis in 
non-infectious conditions such as systemic lupus erythematosus 3, deep vein 
thrombosis and vasculitis 4, 5, cystic fibrosis 6, pre-eclampsia 7, 8, obesity 
associated adipose tissue inflammation 9 and cancer pathogenesis, and how 
ETs might be regulating the disease inflammatory microenvironment. The fact 
that stimulation by a combination of factors such as GM-CSF and LPS or C5a, 
which offers weaker stimulation compared to PMA mediated activation can still 
result in NET release suggested that priming of immune cells can predispose 
them to ET release upon secondary activation 10. It has also been shown that 
several groups of immune cells other than neutrophils, such as macrophages, 
eosinophils, and mast cells are capable of releasing ETs in response to the 
above mentioned stimuli 9, 11-15. 
Macrophage extracellular traps in diseases 
Even though many studies have documented the role of NETs in a variety of 
disease conditions, the importance of METs in diseases are not well studied. 
Macrophage extracellular traps (METs) were recently characterized in 
infectious diseases such as Mannheimia haemolytica infection in Bovines 11 
and in vitro exposure of Staphylococcus aureus to RAW 264.7 macrophage 
cell line 16. Another study reported that human macrophages and monocytes 
can form METs in response to gold nanoparticles 17. The molecular pathways 
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involved in MET release and the role played by METosis in patho-physiology 
of these diseases are yet to be understood. Our lab has previously observed 
that PAD2 is highly expressed in RAW 264.7 macrophage cell line and that 
PAD2 to tend to localize to DAPI poor, euchromatin regions of the 
macrophage nuclei 9.  This finding led to the hypothesis that PAD2 is a primary 
driver of histone hypercitrullination, chromatin decondensation, and ET 
formation in macrophages. Additionally, this hypothesis is further supported by 
our recent genomic study, which provided evidence that both global and 
promoter-specific chromatin decondensation is catalyzed by PAD2 in breast 
cancer cell lines 18.  In the present study, we focused on macrophage 
extracellular trap release process and if the underlying fundamental 
mechanism of chromatin decondensation during MET release is affected by 
peptidylarginine deiminase mediated histone citrullination. 
Role of PADs and histone modifications in ETosis 
PAD enzymes catalyze the conversion of positively-charged arginine residues 
to neutrally-charged citrulline in a hydrolytic reaction termed citrullination or 
deimination. This results in loss of charge at the citrullinated site and can 
dramatically alter the target protein’s tertiary structure as well as protein-
protein interaction 19, 20.  One of the major targets for PAD enzymes in the 
nucleus is the N-terminal tails of histones such as arginine-rich H3 and H4. 
Numerous reports have shown that PAD4 and, more recently, PAD2, mediate 
gene expression via citrullination of histone H4R3 and H3R26, respectively 20, 
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21. The mechanisms by which histone citrullination regulates gene transcription 
are starting to come to light in recent studies. We recently demonstrated that 
PAD2-catalyzed histone citrullination promoted localized chromatin 
decondensation at target gene promoters, thus likely facilitating binding of the 
basal transcriptional machinery 22. Previous studies from our lab and several 
others have shown that PAD4 mediated histone hypercitrullination on a more 
global chromatin level, evidenced by higher levels of Histone H4 Citrulline 3 
(H4Cit3) can promote global chromatin decondensation resulting in NETosis 
during inflammation. In this study, we showed by transmission electron 
microscopy that activation of PAD4 in HL60 granulocyte cells promoted a 
nuclear structural change characterized by the conversion of multi-lobular 
heterochromatic nuclei into a more round euchromatic nuclear pattern 20. 
Additionally, we demonstrated that TNF- tre a tme nt of blood ne utrophils  
resulted in the release of extracellular chromatin that was extensively 
citrullinated at histone H4R3. The link between the H4Cit3 modification and 
ETosis has been proven to be very strong and detection of this modification is 
now routinely utilized to document the presence of ETs in cells and tissues 9, 
20, 23, 24. Recently, the requirement of citrullination in NET formation in vivo was 
recently documented by investigators who showed that PAD4-/- mice have 
impaired ability to form NETs in response to various stimuli. Additionally, the 
investigators found that PAD4-/- mice are more susceptible to bacterial 
infections 25. Extensive studies have previously shown that PAD activity is also 
closely associated with non-infectious immune-mediated inflammatory activity 
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such as that seen in autoimmune arthritis, colitis, and chronic obstructive 
pulmonary disease. 
Role of ETosis in Cancer Pathogenesis 
Immune system pose a double edged sword for cancer progression by either 
helping the body to identify and destroy tumor cells or assisting in promoting 
the tumor progression. Often these functions of immune system in tumor 
pathogenesis is termed as cancer immunoediting 26. Using pediatric Ewing 
sarcoma tissue sections, 27it has been shown that several of the patient 
samples were positive for the presence of NETs released by tumor associated 
neutrophils (TANs) and that the presence of TAN-ETs was significantly 
correlated to metastatic disease. NETs were also attributed to play a role in 
cancer associated thrombosis because different types of cancer can create a 
favorable microenvironment for NET release and these NETs in turn provide a 
scaffold and coagulation pathway stimulus for thrombotic disease to occur 28. 
This study showed that lung and breast carcinoma in mice resulted in 
increased number of blood neutrophils that are prone to releasing NETs and 
that when a minor systemic infection was induced in tumor bearing mice, a 
large amount of NET chromatin was released and caused a prothrombotic 
state in the animal. The proof that NET components can actually sequester 
circulating tumor cells and assist in tumor metastasis came from the study 
conducted by Cools-Lartigue et al 29, which used in vitro models of static and 
dynamic interaction of NET and tumor cells and in vivo model of infection 
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using cecal ligation and puncture. They further showed that the NET assisted 
tumor metastasis can be inhibited by abolishing the NETs through treatment 
with DNAse or a neutrophil elastase inhibitor.  
Tumor associated macrophages 
Current integrated approach to cancer treatment has made it essential to 
further understand the unique role played by tumor microenvironment which 
can favor or block the malignant progression. Cross talk between cancer cells 
and the immune cells in the tumor microenvironment is considered an 
important factor for cancer progression. Immune cells release free radicals, 
such as reactive oxygen species and nitric oxide following activation and these 
molecules can cause DNA damage and gene mutations in tumor cells, helping 
tumor progression. Cancer immune response is predominantly macrophage 
mediated. Macrophages continuously infiltrate into the tumor 
microenvironment and are transitioned into TAMs when stimulated by 
paracrine factors, which are released by cancer cells, other groups of immune 
cells, and fibroblasts.  Macrophages are able to efficiently respond to 
microenvironment signals given their cellular plasticity and exhibit significantly 
altered cell physiology in both innate and adaptive immune response 30. TAMs 
are the key orchestrators of tumor associated inflammation constituting the 
main type of inflammatory cells in tumors 31. The Macrophages can cause 
both anti- and pro-tumor effects through the expression of various signals 
based on the microenvironment cues and phenotypic differentiation into either 
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M1 or M2 types. TAM signature offers a potential therapeutic target and a 
prognostic marker. Clinical studies conducted in breast cancer patients have 
shown that TAMs are significantly correlated with micro-vessel density, 
regional lymph node metastasis, hormone receptor status and tumor grades, 
treatment efficacy, and survival period 32. Increased CD68+ index is predictive 
of high tumor vascularity, nodal metastasis, and decreased duration of 
disease-free survival 33, 34. Mahmoud et al 35 showed in a large cohort study of 
1322 breast cancer patients that TAMs offer significant predictive value for 
breast cancer prognosis. Currently, there are no studies characterizing the 
presence of TAM-ETs and specifically addressing the role of tumor-associated 
macrophage released ETs in tumor microenvironment regulation. Given the 
critical role played by TAMs in tumor progression, we hypothesized that TAMs 
within the human tSCCs may release METs which can further modify the 
tumor microenvironment by recruiting and activating other immune cells and 
by altering tumor cell properties such as migration. 
 
3.3  Materials and Methods 
Cell culture and MET induction 
RAW 264.7 mouse macrophage cells were grown in RPMI 1640 medium 
(Cellgro, Manassas, VA) supplemented with 10% fetal bovine serum 
containing penicillin-streptomycin. Peritoneal macrophages were isolated from 
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wild type and PAD2KO mice using a previously described method 36. Briefly, 
mice were humanly euthanized and fur dampened with povidone-iodine. 
Animal was secured on a dissection board and about 6 ml of sterile PBS was 
injected into the caudal half of the peritoneal cavity. The abdomen was 
massaged for about 20 seconds and using 20 gauge needles the PBS 
containing resident peritoneal macrophages was aspirated out. The cells were 
spun down at 300g for 10 minutes and the cell pellet was washed twice with 
RPMI medium. The cells were resuspended at 2X106 cells/mL concentration 
and placed in the 37oC incubator for 2 hours to allow the macrophages to 
adhere. Then the plates were gently washed with RPMI medium to remove 
non-adherent cells. The macrophages were then grown in a sterile, humidified 
incubator at 37oC and 5% CO2. 
 
To perform IF staining, macrophages were grown on 12 mm glass coverslips 
for 2 days at 37oC (Fisher Scientific, Hanover Park, IL). The RAW 264.7 
macrophages were treated with PMA for four hours, then washed in 1X 
phosphate buffered saline (PBS), fixed in 4% cold paraformaldehyde for 20 
minutes, washed in 1X PBS, and immunofluorescence staining was performed 
as described below. 
MET isolation and Quantitation 
METs were isolated from ET rich supernatant using a previously described 
method. MET DNA was quantitated using a Sytox Green Assay (REF-NET 
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epithelial paper). Briefly, following PMA stimulation, medium was collected 
with extensive pipetting. The cells and cellular debris was centrifuged down in 
300g for 10 minutes and the ET containing supernatant was collected and the 
extracellular DNA in the supernatant measured by Sytox Green Assay. In 
order to isolate METs, macrophages were treated with PMA, medium was 
removed after 4 hours of treatment, and the cells were gently washed with 
RPMI twice. 200 μL of fresh RPMI was added to the cells and extensively 
pipetted to collect the MET smear present over the macrophage monolayer. 
The cell debris was separated by 300g centrifugation for 10 minutes and the 
MET DNA in the supernatant was quantitated using the Sytox Green assay. 10 
μg of MET DNA containing supernatant was used for treating macrophages 
and A431 cancer cells to evaluate the effects of METs in immune and cancer 
cell properties. Equal amount of RPMI supernatant from DMSO treated 
macrophages was used as a control.  
Immunohistochemistry (IHC) and Immunofluorescence (IF) 
IHC and IF experiments followed our previously described protocol 37.  Briefly, 
paraffin embedded tissue sections from human tSCC were deparaffinized and 
rehydrated in 3X 5 minute washes in xylene followed by single sequential 5 
minute washes in 100, 95, and 75% EtOH. An endogenous peroxidases 
quenching step was done by incubating the slides for 10 minutes in 0.5% 
hydrogen peroxide in cold methanol. We used a citrate buffer antigen retrieval 
method which was performed by boiling slides two times for 10 minutes in 
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0.01M sodium citrate pH 6.8 and, after cooling, slides were washed in 1X 
PBS. Tissue slides and fixed coverslips containing RAW264.7 cells were then 
blocked in 10% normal goat serum and 2X casein (Vector Labs, Burlingame, 
CA) for 20 minutes at room temperature in a humidified microprobe chamber.  
Slides were blotted to remove excess blocking solution and then primary 
antibody diluted in 1X PBS was applied to the slides for 2 hours at room 
temperature.  Slides or cover slips were then stained with primary antibodies 
(anti-PAD2 - ProteinTech #122100-1-AP, anti-histone H4 Citrulline 3 - 
Millipore-Upstate # 07-596). Following 3X washing with 1X PBS, slides were 
incubated with a 1:200 dilution of secondary antibody labelled with peroxidase 
for IHC or appropriate fluorophore (in 1X PBS) for confocal imaging for 1 hour 
at room temperature and then washed 3X in 1X PBS. For IHC, slides were 
incubated in DAB chromagen (Vector Labs) solutions according to the 
manufacturer’s protocol, washed and then counterstained with Gill’s 
hematoxylin and coverslipped. For each experiment, duplicate slides were 
treated with control rabbit IgG antibody at the appropriate concentration as a 
negative control. For confocal imaging, DAPI and Sytox Green were used as 
DNA staining reagents. We observed that Sytox Green offered promising 
visualization of decondensed chromatin ETs compared to the weaker staining 
by DAPI.  
 
In order to quantitate changes in levels of citrullinated histones during MET 
induction in WT and PAD2KO macrophages, a time course experiment was 
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performed, evaluating H4Cit3 immunofluorescence intensity at 0, 2, 6 and 24 
hours. Primary peritoneal macrophages were treated with 2 μg/ml of PMA, 
fixed and H4Cit3 immunofluorescence staining was performed using the 
method described above. Five different fields from each time point were 
imaged using confocal microscopy and the mean integrated fluorescence 
intensity was calculated using ImageJ software analysis as previously 
described by Gavet and Pines 38. The results were then analyzed by one-way 
ANOVA to detect statistical differences and a p-value < 0.01 was considered 
significant. The results are presented as mean ± Standard deviation or mean ± 
Standard error. 
 
3.4 Results and Discussion 
PAD2 is highly expressed in RAW 264.7 and peritoneal primary 
macrophages and is a potential candidate for MET release regulation 
We previously have shown the strong expression of PAD2 mRNA and PAD2 
protein in RAW 264.7 macrophage cells 9. In the current study, we also found 
that primary peritoneal macrophages, similar to RAW 264.7 macrophage cell 
line, are also highly positive for nuclear and cytoplasmic expression of PAD2 
(Figure 3.1A and 3.1B). We noticed that PAD2 appeared to localize, in part, 
to DAPI-poor euchromatic regions of the macrophage nuclei while PAD4 was 
found only weakly expressed these macrophage cells.  
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Figure 3.1: PAD2 expression in cultured RAW 264.7 macrophage cells 
and in mouse primary peritoneal macrophages. (A) RT-PCR for PAD2 and 
PAD4 mRNA expression in cultured RAW 264.7 macrophages and primary 
peritoneal macrophages. Two unique primer sequence sets were used to test 
for PAD2 and PAD4 mRNA expression levels. RAW 264.7 macrophages were 
found to strongly express PAD2 mRNA. GAPDH mRNA expression levels 
were used as the internal control for RT-PCR. (B) Anti-PAD2 
immunofluorescence labeling shows positive staining in macrophages. Nuclei 
are stained with DAPI. 
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PAD2KO macrophages show an impaired ability to release METs 
In order to test the role of PAD2 in MET release, we collected WT and 
PAD2KO primary peritoneal macrophages from mice and treated them with 
PMA to induce MET release. The treated macrophages were stained with Diff-
Kwik dye to evaluate the number and morphological characteristics of METs. 
We found that the number of METs was reduced in PAD2KO macrophages 
and the PAD2KO METs appeared more condensed, less branching, and often 
failed to form the classically described tangled web-like pattern of ETs (Figure 
3.2). On the other hand, for WT METs, the released extracellular DNA strands 
were found to be forming complex webs, or, interestingly clusters of vesicular 
bodies which are presumed to be DNA-Histone complexes. 
 
METs contain high levels of citrullinated histones which is reduced upon 
PAD2 deletion 
METs released as a result of PMA treatment were stained with anti-H4Cit3 
antibody. H4Cit3 is a site specific histone citrullination which has been 
characterized as a marker of ETs in several previous studies. The METs 
released by primary PMΦ were highly positive for H4Cit3 staining (Figure 
3.3A). Using confocal z-stack 3-dimensional microscopy we further evaluated 
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the METs and showed that citrullinated histone rich METs appears to interact 
with other macrophages in the vicinity (Figure 3.3B). These METs often form  
long linear or branching web like structures extending far beyond the cell 
borders which are delineated with Phalloidin staining (Figure 3.3C), potentially 
providing a scaffold for other macrophages to bind and modify the 
inflammatory microenvironment. In order to evaluate the role of PAD2 in 
histone citrullination during MET formation, a time course experiment was 
performed in which the peritoneal macrophages were treated with PMA for 30 
minutes, 2 hours or 4 hours and were stained with anti-H4Cit3 antibody. We 
found by H4Cit3 IF staining that PAD2KO PMΦ nuclei showed reduced levels 
of histone citrullination at 30 minutes, 2 hours and 4 hours time points as 
evidenced by weaker H4Cit3 staining intensity (data not shown). These data 
supported our hypothesis that PAD2 is critical in mediating histone 
hypercitrullination during MET induction process. 
PAD2 deletion and drug-mediated PAD inhibition reduce chromatin 
decondensation 
One of the morphological changes seen after PMA stimulation during MET 
production is nuclear chromatin decondensation. PADs are known to play a 
role in chromatin decondensation and our lab has previously shown that PAD4 
is involved in chromatin decondensation in neutrophils during NET release. 
We wanted to see if a PAD inhibitor treatment or PAD2 deletion will cause a 
reduction in PMΦ chromatin decondensation following PMA stimulation.  
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Figure 3.2: Peritoneal macrophages release extracellular traps (ETs) in 
response to PMA stimulation. Diff-Kwik staining shows web of extracellular 
DNA released by WT macrophages forming an interconnected scaffold of thin 
chromatin fibers compared to the DMSO control cells (Figure 3.2a and 3.2b). 
Occasionally there are vesicular bodies presumed to be DNA-histone 
complexes released by PMA treated macrophages (Figure 3.2c). The 
PAD2KO macrophages show reduced number of macrophages releasing 
METs with more condensed morphological appearance compared to WT 
METs (Figure 3.2e).  
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Figure 3.3: METs are highly positive for citrullinated histones and MET 
web interact with other macrophages in their vicinity. Primary PMΦ cells 
were cultured on coverslips in RPMI medium and stimulated with PMA for four 
hours.  The METs were visualized by DAPI + Anti-H4Cit3 antibody staining. 
Phalloidin staining for actin is used to visualize the cytoplasmic borders. 
Intense staining for H4Cit3 is observed in METs. The nuclei of macrophages 
appear to be distended following PMA treatment and also contain increased 
H4Cit3 levels. Figure 3.3B shows a surface plot of confocal z-scan imaging of 
H4Cit3 levels in METs. Figure 3.3C shows confocal Z-stack imaging of METs 
released by primary PMΦ extending beyond cell borders. 
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We treated RAW 264.7 macrophages for 24 hours with a new generation of 
PAD inhibitor BB-CLA, a PAD inhibitor at a concentration of 2.5 µM/ml and 
both the control cells and the BB-CLA treated cells were further treated with 
PMA for 30 minutes. The chromatin structure was visualized by Sytox Green 
staining and the cells were imaged using confocal microscopy. Both BB-CLA 
treated cells and PAD2KO PMΦ showed a more condensed chromatin pattern 
and smaller nuclear size compared to the wild type PMΦ and no-drug 
treatment group (Figure 3.4). In order to quantitate the ability of WT, PAD2 
deleted PMΦ and PAD-inhibitor treated macrophages to release METs, a 
Sytox Green based DNA quantitation assay was performed. PAD2KO PMΦ 
and BB-CLA treated macrophage cells showed reduced MET release 
compared to the WT macrophages following PMA stimulation (Figure 3.5). 
This further confirmed the role of PAD2 played specifically in MET release. 
 
PAD2 expression and H4Cit3 levels in TAMs in human tSCC 
Though tumor associated NETs were previously described, there are no 
studies published characterizing tumor associated METs (TAM-ETs) or the 
role of histone citrullination in TAM-ETs. Head and neck squamous cell 
carcinomas are known to be associated with a predominant inflammatory 
component and we decided to evaluate human tongue SCC sections by 
immunostaining and confocal microscopy for the presence of METs. 
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Immunohistochemical staining for PAD2 strongly stained cytoplasm and nuclei 
of the immune cells surrounding the carcinoma cell islands. The cancer cells 
themselves showed weak cytoplasmic and nuclear staining for PAD2. 
Scattered tumor associated macrophages showed moderate to intense H4Cit3 
nuclear staining and extranuclear streaming pattern (Figure 3.6). Using 
confocal microscopy, we found that MET-like structures exist in tSCC sections 
which are highly positive for citrullinated histones (Figure 3.7). To confirm the 
identity of the cells that are releasing these traps, we costained the tumor 
sections with F4/80, a macrophage marker, and DAPI, and found that the trap 
rich regions, which have streaming DNA and are stained positively for DAPI, 
were associated with F4/80 positive stained cells, and thus confirming that 
these ETs are indeed METs (Figure 3.8). A more specific marker for tumor 
associated macrophage that has been well described in the literature is CD68. 
We then costained the tSCC sections with CD68, anti-H4Cit3 and DAPI and 
imaged using confocal microscopy. We found that H4Cit3 and DAPI positive 
extracellular streaming structures consistent with METs are associated with 
CD68+ macrophages, which are associated with tumor cell clusters (Figure 
3.9A). It is also interesting to note that we were able to identify MET sparse 
and MET rich areas within the same tissue section suggesting the inherent 
variability of the tumor microenvironment in tSCC which may further contribute 
to tumor heterogeneity (Figure 3.9B).  
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Figure 3.4. PAD2 deletion and drug-mediated inhibition affect nuclear 
chromatin decondensation in macrophages during MET induction. RAW 
264.7 cells were treated with the PAD inhibitor BB-CLA for 24 hours. 
Untreated RAW 264.7 cells, BB-CLA pre-treated RAW 264.7 cells, PAD2 KO 
PMΦ and WT PMΦ were then treated with PMA for 30 minutes to observe the 
early changes during MET induction. The cells were stained with Sytox Green 
dye to visualize nuclear chromatin structure and nuclear size. 
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Figure 3.5: Quantitation of MET release by WT, PAD2 KO PMΦ, and PAD 
inhibitor treated macrophages. The PMΦ cells from WT mice and PAD2KO 
mice were cultured for 24 hours and treated with PMA to induce MET 
formation. BB-CLA-PMA group received a 24 hour pretreatment with the PAD 
inhibitor BB-CLA. After 4 hours of PMA treatment MET containing 
supernantant was collected and the MET DNA was quantitated using Sytox 
Green assay. The florescent intensity values were standardized as a ratio to 
the florescent intensity observed in WT-DMSO control group and plotted as 
mean ratio ± SE.  
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Figure 3.6: Immunohistochemical staining for H4Cit3 levels in human 
tongue squamous cell carcinomas. tSCC tissue sections from 12 different 
human patients were evaluated for PAD2 and H4Cit3 staining by 
immunohistochemistry. Non-specific IgG was used as the negative control. 
Immune cells surrounding tumor cell clusters showed strong cytoplasmic and 
nuclear staining for PAD2. H4Cit3 antibody stained a subset of tumor-
associated inflammatory cells which had morphologic features consistent with 
macrophages. H4Cit3 staining varied in its intensity often showing intense 
nuclear staining and extranuclear streaming and appeared to extend beyond 
cell borders. 
 
   129 
 
   130 
 
 
 
 
 
 
 
 
Figure 3.7: H4Cit3 immunofluorescence staining in extracellular traps 
associated with tSCC inflammation. tSCC tissue sections from 12 different 
human patients were evaluated by costaining for the ET marker H4Cit3 and 
DNA marker DAPI and the immunofluorescence images were acquired by 
confocal microscopy.  
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Figure 3.8: Costaining for macrophage marker F4/80 and DAPI to 
evaluate METs in tSCC sections. tSCC sections were stained with 
macrophage marker antibody, anti-F4/80 and nuclear stain DAPI and imaged 
using a confocal microscope. Scattered areas within the tumor associated 
inflammatory areas show the presence of extracellular DNA streaming forming 
an interconnected complex scaffold originating from nuclei of macrophages. 
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Figure 3.9:  Costaining for TAM marker CD68, H4Cit3 and DAPI in METs 
associated with tSCC inflammation. (A) tSCC tissue sections were 
processed and costained with antibodies against CD68, H4Cit3 and the 
nuclear stain DAPI (B) Overall evaluation of the entire tissue section from each 
patient tissue sample showed that there are occasional MET rich pockets 
within the tumor tissue. Costaining for CD68, H4Cit3 and DAPI show that 
these extracellular traps are associated with CD68+ TAMs. 
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More recently, a term called “cellular hypercitrullination” is used in the context 
of rheumatoid arthritis. A study by Romero et al suggested that two main pore-
forming pathways are involved in cellular hypercitrullination, namely, perforin 
and the membrane attack complex (MAC) 39. Our study is the first to show that 
TAMs in human carcinomas as such tSCC can be activated to release METs 
and these METs are highly positive for citrullinated histones. A previous study 
suggested the possibility that Ewing Sarcoma associated TAN-ETs may be 
playing an anti-tumorigenic role by NET-mediated immune cell capture and 
prevention of metastasis or alternatively NET associated components acting 
as facilitators for metastasis 27. Several components of NETs can be cytotoxic 
to cancer cells, for example, the tumoricidal effect on melanoma by MPO was 
shown by Odajima et al. 40. Further studies are needed to clearly delineate the 
pro or anti-tumorigenic effects of MET components.  
3.5 Conclusions 
We identified PAD2 as a critical mediator during MET release using both 
macrophage cell lines and primary resident macrophages. Hypercitrullination 
of histones as evidenced by high H4Cit3 levels were observed in METs. The 
PAD2KO PM cells showed decreased efficiency in producing METs and a 
similar effect was also observed in macrophages treated with a PAD enzyme 
inhibitor. We further show that MET rich areas are present within human tSCC 
tissue sections and these tumor METs also contain high levels of citrullinated 
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histones. METs may play a critical role in regulating tumor associated 
inflammatory microenvironment and MET components may act as DAMPs, 
thus regulating tumor cell migration and immune cell recruitment. A summary 
of the potential functional roles for METs released into the tumor 
microenvironment is given in Figure 3.10. Previous studies have shown that 
histones can act as DAMPs and activate TLR4 signaling in immune cells thus 
further regulating immune cell – tumor cell paracrine signaling network. A MET 
rich environment may also regulate tumor cell properties such as migration 
and metastasis. PAD inhibitors may be used in vivo to dampen the MET 
release activity of TAMs and thus assist in immune modulation of tumor 
inflammatory microenvironment.  
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Figure 3.10: Proposed functional roles of METs in regulation of tumor 
microenvironment. METs may be critical mediators of tumor associated 
inflammation thus regulating tumor microenvironment. Our study shows that 
nuclear PAD2 is involved in chromatin decondensation during MET induction. 
The resulting extracellular traps are rich source of histones and nuclear 
proteins including citrullinated histones. Previous studies have shown that 
histones can act as DAMPs and activate TLR4 signaling activating adjacent 
macrophages and further regulating immune cell – tumor cell paracrine 
signaling. A MET rich environment may also regulate tumor cell properties 
such as migration and metastasis. PAD inhibitors may be used in vivo to 
dampen the MET release activity of TAMs and thus assist in immune 
modulation of tumor inflammatory microenvironment.  
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4.1 Abstract 
PAD4-mediated hypercitrullination of histone H4 arginine 3 (H4R3) has been 
previously found to promote the formation of Neutrophil Extracellular Traps 
(NET) in inflamed tissues and the resulting histone H4 citrulline 3 (H4Cit3) 
modification is thought to play a key role in extracellular trap (ET) formation by 
promoting chromatin decondensation. In addition to neutrophils, macrophages 
have also recently been found to generate functional extracellular traps 
(METs).  However, a role for PADs in ET formation in macrophages has not 
been previously described. Transcripts for PAD2 and PAD4 are found in 
mature macrophages and these cells can be induced to citrullinate proteins, 
thus raising the possibility that PADs may play a direct role in ET formation in 
macrophages via histone hypercitrullination. In breast and visceral white 
adipose tissue from obese patients, infiltrating macrophages are often seen to 
surround dead adipocytes forming characteristic “crown-like structures” (CLS) 
and the presence of these lesions is associated with increased levels of 
inflammatory mediators. In light of these observations, we have initiated 
studies to test whether PADs are expressed in CLS macrophages and 
whether these macrophages might form METs. Our preliminary findings show 
that PAD2 (and to a lesser extent, PAD4) is expressed in both in the 
macrophage cell line (RAW 264.7) and in CLS lesions. Additionally, we 
provide evidence that macrophage-derived extracellular histones are seen 
around presumptive macrophages within CLS lesions and that these histones 
contain the H4Cit3 modification. These initial findings support our hypothesis 
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that obesity-induced adipose tissue inflammation promotes the formation of 
METs within CLS lesions via PAD-mediated histone hypercitrullination. 
Subsequent studies are underway to further validate these findings and to 
investigate the role in PAD-mediated MET formation in CLS function in the 
mammary gland. 
4.2 Introduction 
ETosis is a recently described cell death-associated phenomenon that results 
in the release of a complex lattice of chromatin that contains DNA, histones, 
and other associated proteins 1-3. These extracellular chromatin webs can be 
used to entrap and kill microbial organisms. Initially, this phenomenon was 
described in neutrophils, termed NETosis (Neutrophil Extracellular Traps), but 
subsequent studies have found that this mechanism also exists in other cell 
types such as macrophages, eosinophils, and mast cells. Given the ever-
expanding array of cell types that can form extracellular traps, this activity is 
now more generally referred to as ETosis. Various infectious agents such as 
bacteria, fungi, and protozoa, have been found to induce ETosis, as have 
cytokines, such as IL-8, and chemicals, such as phorbol myristate acetate 
(PMA) 4.  
 
At the molecular level, ETs were first shown to be comprised of decondensed 
DNA scaffolds and various neutrophil granular proteins 4. Later proteomic 
studies further concluded that ETs contain histones (the most abundant 
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fraction), elastase, glycolytic enzymes, and several other cytosolic proteins 5. 
Immunofluorescence studies have also shown additional components in ETs 
such as NADPH oxidase subunits, pentraxin-3, and cathelicidin. Interestingly, 
the localization of these proteins to NETs was not supported by subsequent 
biochemical studies, suggesting that some of these components may be 
loosely associated with ETs  6. While the precise mechanisms underlying ET 
induction and formation are not completely understood, several morphological 
features of ETosis have been observed across various studies.  These 
features include loss of distinct segregation of euchromatin and 
heterochromatin, disappearance of the lobular nuclear architecture in 
neutrophil nuclei, granular membrane disruption, and nuclear membrane 
swelling. ET induction is thought to occur when proteolytic enzymes are 
released from cytosolic granules where these enzymes then cause a collapse 
of the nuclear envelope, leading to disruption of plasma membrane integrity 
and, eventually, release of ETs into the extracellular space 7, 8. 
While many studies have now documented a role for NETs in an array of 
activities, much less is known about ETosis in other cell lines such as 
macrophages. Two recent studies found that the bacterial organisms 
Histophilus somni and Mannheimia haemolytica can induce ETs in bovine 
macrophages (METs) 9, 10. Additionally, another study showed that human 
THP-1-derived macrophages and the RAW 264.7 macrophage cell line formed 
METs in response to E. coli toxins. Interestingly, while MET formation has 
been documented in tissue macrophages, it has yet to be reported in 
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peripheral blood monocytes 10.  
 
PAD enzymes catalyze the conversion of positively-charged arginine residues 
to neutrally-charged citrulline in a hydrolytic reaction termed citrullination or 
deimination. The resulting loss of charge at this site can dramatically alter the 
target protein’s tertiary structure as well as its ability to interact with other 
proteins 11, 12. The N-terminal tails of histones such as H3 and H4 are arginine-
rich and appear to represent major target for PAD enzymes. For example, 
numerous reports have shown that PAD4 and, more recently, PAD2, regulate 
gene expression via citrullination of histone H4R3 and H3R26, respectively 12, 
13. While the mechanisms by which histone citrullination regulates gene 
transcription are not fully understood, we recently demonstrated that PAD2-
catalyzed histone citrullination promoted localized chromatin decondensation 
at target gene promoters, thus likely facilitating binding of the basal 
transcriptional machinery 14. On a more global level, we have also recently 
shown that activation of PAD4 in neutrophils promotes histone 
hypercitrullination, global chromatin decondensation, and NET formation 12. In 
this previous study, we showed by transmission electron microscopy that 
activation of PAD4 in HL60 granulocytes promoted the conversion of multi-
lobular heterochromatic nuclei into a more round euchromatic nuclear pattern 
12. Additionally, we demonstrated that TNF-α treatment of blood neutrophils 
resulted in the release of extracellular chromatin that was extensively 
citrullinated at histone H4R3. The link between the H4Cit3 modification and 
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NET formation is very strong and this modification is now routinely utilized to 
document the presence of ETs in cells and tissues 12, 15. In addition to TNF- α, 
LPS and H2O2 have also been shown to induce PAD-mediated histone 
deimination 15. Importantly, the requirement of citrullination in NET formation in 
vivo was recently documented by investigators who showed that PAD4-/- mice 
have reduced ability to form NETs in response to various stimuli. Additionally, 
the investigators found that  these mice are more susceptible to bacterial 
infections 16. More generally, PAD activity is also closely associated with non-
microbial induced immune-mediated inflammatory activity such as that seen in 
autoimmune arthritis, colitis, and chronic obstructive pulmonary disease. Along 
these lines, excessive PAD-mediated ETosis has also recently been found to 
play a role in deep vein thrombosis and cystic fibrosis. 17 
 
Obesity is a major public health concern and, among other things, is a risk 
factor for hormone receptor-positive breast cancer in postmenopausal women 
18, 19. Numerous studies in obese humans and animals have shown that 
macrophages infiltrate visceral adipose tissue and surround dead adipocytes 
forming a characteristic “crown like structure” (CLS) morphology. These 
macrophages are believed to primarily function at these sites by “cleaning up” 
the remnants of dead/dying adipocytes via phagocytosis of lipids, cytoplasmic 
debris, and karyorrhectic remnants 20. Additionally, these immune cells 
produce proinflammatory mediators that are found in the circulation of obese 
women and have been linked to breast cancer progression.  
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Recent studies have shown that CLS lesions occur in white adipose tissue of 
the breast in obese women and in the mammary gland of experimental models 
of obesity 21, 22. Importantly, in mouse models of obesity, CLS occur in 
association with activation of NF-κB and elevated levels of inflammatory 
mediators including TNF-α, IL-1β, and COX-2 23. Increased levels of TNF-α at 
these sites is thought to enhance inflammatory activity due to a paracrine 
signaling loop between TNF-α, saturated fatty acids, and adipocytes 24. Given 
that TNF-α can induce extracellular trap formation in neutrophils, that PADs 
are intimately associated with inflammation, and that macrophages can form 
ETs, we predicted that macrophages may undergo ETosis in CLS lesions. As 
outlined below, we performed a preliminary study to test this hypothesis. Our 
findings suggest that METs do form in CLS structures, thus laying the 
groundwork for future studies to investigate the functional role for METs in the 
resolution of inflamed white adipose tissue in the mammary gland. 
 
4.3 Materials and methods 
 
RAW 264.7 cell culture and MET induction 
RAW 264.7 mouse macrophage cells were grown in RPMI 1640 (Cellgro, 
Manassas, VA) supplemented with 10% fetal bovine serum containing 
penicillin-streptomycin. The cells were grown in a sterile, humidified incubator 
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and maintained in these conditions at 37oC and 5% CO2. To perform IF 
staining, macrophages were grown on 12 mm glass coverslips for 2 days at 
37oC (Fisher Scientific, Hanover Park, IL). The RAW 264.7 macrophages were 
treated with recombinant TNF- α (20 ng/ml, R&D systems, Minneapolis, MN, 
USA) for two hours, then washed in 1X  phosphate buffered saline (PBS), 
fixed in 4% cold paraformaldehyde for 20 minutes, washed in 1X PBS,  and 
immunofluorescence staining was performed as described below.  
 
Mammary gland adipose tissue from obese mice 
Mammary gland adipose tissue sections were prepared from a dietary model 
of obesity as described previously 22, 25. Ovariectomized C57BL/6J mice 
(Jackson Laboratories) at 5 weeks of age were given high fat diet (60 kcal% 
fat, D12492i, Research Diets) to generate obese mice. Mice were fed ad 
libitum for 10 weeks and sacrificed to collect mammary gland tissue. Tissue 
samples were formalin fixed for histological and immunohistochemical 
analyses. The animal protocol was approved by the Institutional Animal Care 
and Use Committee at Weill Cornell Medical College.  
 
mRNA isolation and RT-PCR 
RNA was isolated from the RAW 264.7 macrophage cells using the Qiagen 
RNeasy mini kit, including on-column DNAse treatment to remove genomic 
DNA (Qiagen # 74104). The purified RNA was reverse-transcribed using the 
Applied Biosystems High Capacity RNA-to-cDNA kit according to 
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manufacturer’s protocol (Applied Biosystems # 4387406, Foster City, CA). The 
cDNA (100 ng) was mixed with Go-Taq DNA polymerase (Promega # M3005, 
Madison, WI) and primer set. The following primer pairs were used (size of the 
amplicons are in parentheses): PAD2 primer set #1 (400 bp): Fwd - 5’-
AGAAGGGAGGCTCTGAGGTC-3’and Rev - 5’-
CTGGCCAGAGAATTGAGGAC-3’; PAD2 primer set #2 (188 bp): Fwd - 5’-
CAAGATCCTGTCCAATGAGAG-3’ and Rev - 5’-
ATCATGTTCACCATGTTAGGGA-3’; PAD4 primer set #1 (406 bp): Fwd - 5’-
TCTCCCTGCTGGACAAGTCT-3’ and Rev - 5’-
AGCCCAGTGAGCTCTGACAT-3’; PAD4 primer set #2 (193 bp): Fwd - 5’-
CTACTCTGACCAAGAAAGCC-3’ and Rev - 5’-
ATTTGGACCCATAACTCGCT-3’; GAPDH primer set #1 (324 bp): Fwd - 5’-
CCCACTAACATCAAATGGGG-3’ and Rev - 5’-
ATCCACAGTCTTCTGGGTGG-3’; and GAPDH primer set #2 (209 bp): Fwd - 
5’-GGGCATCTTGGGCTACAC-3’ and Rev - 5’-
GGTCCAGGGTTTCTTACTCC-3’. PCR was performed using the following set 
up: 5 minutes at 95°C, 30 cycles of (30 s, 94°C; 30 s, 58°C; 30 s, 72°C), 5 
minutes at 72°C. The PCR products were analyzed on a 1% agarose gel using 
Geldoc (Biorad) software.  
 
Immunohistochemistry (IHC) and Immunofluorescence (IF) 
IHC and IF experiments followed our previously described protocol 26.  Briefly, 
paraffin embedded tissue sections were deparaffinized and rehydrated in 3X 5 
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minute washes in xylene followed by single sequential 5 minute washes in 
100, 95, and 75% EtOH. Slides were then incubated for 10 minutes in 0.5% 
hydrogen peroxide in methanol to quench endogenous peroxidases.  Antigen 
retrieval was performed by boiling slides 2X for 10 minutes in 0.01M sodium 
citrate pH 6.8 and, after cooling, slides were washed in 1X PBS. Tissue slides 
and fixed coverslips containing RAW264.7 cells were then blocked in 10% 
normal goat serum and 2X casein (Vector Labs, Burlingame, CA) for 20 
minutes at room temperature in a humidified microprobe chamber.  Slides 
were blotted to remove excess blocking solution and then primary antibody 
diluted in 1X PBS was applied to the slides for 2 hours at room temperature.  
Slides or cover slips were then stained with either anti-PAD2 (ProteinTech 
#122100-1-AP, Chicago, IL) at a 1:100 dilution, anti-PAD4 (Sigma-Aldrich # 
P4749) at a 1:100 dilution or with anti-histone H4 Citrulline 3 (Millipore-Upstate 
# 07-596) at a 1:100 dilution. Following 3X washing with 1X PBS, slides were 
incubated with a 1:200 dilution of biotinylated secondary antibody (in 1X PBS) 
for 1 hour at room temperature and then washed 3X in 1X PBS. For IHC, 
slides were incubated in DAB chromagen (Vector Labs) solutions according to 
the manufacturer’s protocol, washed and then counterstained with Gill’s 
hematoxylin and coverslipped. For each experiment, duplicate slides were 
treated with control rabbit IgG antibody at the appropriate concentration as a 
negative control. For immunofluorescence, slides were incubated in 
streptavidin conjugated-488 or 555 (Invitrogen), washed and then mounted 
using Vectashield containing DAPI (Vector Labs). As a negative control, 
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duplicate slides were treated with control rabbit IgG at the appropriate 
concentrations.  
 
In order to quantitate changes in levels of citrullinated histones following TNF-
α treatment, a time course experiment was performed evaluating H4Cit3 
immunofluorescence intensity at 0, 2, 6 and 24 hours. RAW 264.7 
macrophages were treated with 20 ng/ml of TNF-α, fixed and H4Cit3 
immunofluorescence staining was performed using the method described 
above. Five different fields  from each time point were imaged using confocal 
microscopy and the mean integrated fluorescence intensity was calculated 
using ImageJ software analysis as previously described by Gavet and Pines 
27. The results were then analyzed by one-way ANOVA to detect statistical 
differences and a p-value < 0.01 was considered significant. All values are 
presented as mean ± Standard deviation.  
4.4 Results and Discussion 
TNF-α appears to induce MET formation in RAW 264.7 macrophages 
Given that TNF-α induces ET formation in neutrophils, we first tested whether 
TNF-α  could promote ET formation in the RAW 264.7 macrophage cell line. 
As shown in Figure 4.1A, we found that TNF-α treatment led to DAPI-stained 
chromatin in characteristic strands outside of ~5-10% of the phalloidin-bound 
RAW264.7 cells. Two different microscopic fields from 2 hour treatment 
groups are shown in Figure 4.1 as representative images. By contrast, these 
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characteristic strands were not seen in untreated control cells. This 
observation supports the hypothesis that TNF- α induced the release of 
chromatin from the cell nucleus into the extracellular space. As a further test of 
this hypothesis, we then stained the TNF- α -treated RAW264.7 cells with the 
anti-H4Cit3 antibody. Results show that the extracellular chromatin appeared 
to be extensively citrullinated at H4R3, thus suggesting that PAD-mediated 
histone hypercitrullination promotes ETosis in macrophages. In an effort to 
quantitate the extent to which TNF-α promoted the formation of extracellular 
chromatin in RAW264.7 cells, we quantitated the staining intensity for the anti-
H4Cit3 antibody at different time points following treatment. Results show that 
the mean integrated fluorescence intensity at 2, 6, and 24 hours was 
significantly increased (as determined by ANOVA) when compared to the 0 
hour time point (p<0.01). We also note that the H4Cit3 intensity gradually 
increased until the 6 hour time point, while levels were lower at the 24 hour 
time point. This result supports the hypothesis that, as with neutrophils, TNF-α 
stimulates histone hypercitrullination and ETosis in macrophages.  
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Figure 4.1: (A) H4Cit3 immunofluorescence staining in RAW 264.7 
macrophages following 0 and 2 hour TNF-α treatment. Cultured RAW 
264.7 macrophage cells appear to form METs following TNF- α stimulation 
and these METs contain citrullinated histones. DAPI staining (blue) shows that 
DNA extends beyond the Phalloidin-stained cell borders. Anti-Histone H4Cit3 
staining shows presence of citrullinated histones within METs (Arrows). Two 
separate fields from the 2 hour treatment group (Fields 1 and 2) are included 
for reference. 
(B) Integrated anti-H4Cit3 fluorescence intensity quantitation at 0, 2, 6, and 24 
hours of TNF-α treatment. The RAW 264.7 macrophages were treated with 20 
ng/ml of TNF-α, fixed, stained with the anti-H4Cit3 antibody, and imaged by 
indirect immunofluorescence at the indicated time points. Five unique fields 
were imaged by confocal microscopy at each time point and the mean 
integrated fluorescence intensity was calculated using ImageJ software 
analysis. Results were analyzed by ANOVA and the graphs represent mean ± 
standard deviation (*p-value < 0.01). 
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PAD2 is a likely candidate for catalyzing histone hypercitrullination 
during ETosis in macrophages  
While PAD4 is the only PAD family member to have been shown to be 
required for ETosis, both PAD2 and PAD4 have been previously shown to be 
expressed in macrophages. Therefore, as an initial investigation into which 
PAD family member may catalyze ET production in RAW264.7 cells, we first 
investigated mRNA expression levels of PAD2 and PAD4 in this cell line. 
Surprisingly, RT-PCR analysis found that PAD4 expression was very low in 
RAW264.7 cells (Figure 4.2A), suggesting that this family member may not 
play a critical role in macrophage function. We note, however, that we have 
yet to test for PAD4 levels in in vivo-derived macrophages. Given the high 
level of PAD2 mRNA observed in these cells, we then carried out indirect 
immunofluorescence to test whether RAW264.7 macrophages also expressed 
PAD2 protein. Results showed PAD2 staining was strong in these cells 
(Figure 4.2B) and appeared to localize, in part, to DAPI-poor euchromatic 
regions of the RAW 264.7 cell nucleus (Figure 5.2B, bottom right panel). 
While not conclusive, this finding supports the hypothesis that PAD2 is a 
primary driver of histone hypercitrullination, chromatin decondensation, and 
ET formation in macrophages. We note that the localization of PAD2 to the cell 
nucleus fits well with this hypothesis. Additionally, this hypothesis is further 
supported by our recent finding that both global and promoter-specific 
chromatin decondensation is catalyzed by PAD2 in breast cancer cell lines 14.  
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Figure 4.2: PAD2 expression in cultured RAW 264.7 macrophage cells. 
(A) RT-PCR for PAD2 and PAD4 mRNA expression in cultured RAW 264.7 
macrophages. Two unique primer sequence sets were used to test for PAD2 
and PAD4 mRNA expression levels. RAW 264.7 macrophages were found to 
strongly express PAD2 mRNA. GAPDH mRNA expression levels were used 
as the internal control for RT-PCR.  
(B) Anti-PAD2 immunofluorescence labeling shows positive staining in the 
nucleus and cytoplasm of RAW 264.7 macrophages. Nuclei are stained with 
DAPI. 
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Evidence supporting the hypothesis that METs exist in mouse mammary 
gland CLS lesions  
Our findings in the RAW264.7 cell line suggested that PAD2-catalyzed histone 
hypercitrullination may promote ETosis in CLS-localized macrophages. In 
order to begin testing this hypothesis, we next investigated whether PAD2 was 
expressed in the nucleus of macrophages in CLS lesions. Results show that 
PAD2 expression appeared to be robust in these cells (Figure 5.3). 
Importantly, similar to the RAW264.7 cells, PAD2 was found to concentrate in 
the DAPI-poor regions of the presumptive macrophage cell nucleus, again 
suggesting that PAD2 localizes to euchromatic regions of the nucleus. We 
then stained these samples with the anti-H4Cit3 antibody and found positive 
staining for the histone H4Cit3 modification extending from numerous CLS cell 
nuclei (Figure 4.4). This staining is highlighted by arrows in the two 
representative images (Figure 4.4, Field 1 and Field 2) and appears to 
extend into the extracellular space between CLS cells. In order to more 
precisely refine the localization of H4Cit3-stained chromatin, we next carried 
out immunohistochemical staining of the CLS-containing sections using the 
anti-histone H4Cit3 antibody. Results showed that CLS cell nuclei were 
frequently stained with this antibody (Figure 4.5). Importantly, the anti-H4Cit3 
staining is particularly intense in fragmented nuclear particles and, in such 
cases, the staining appeared to extend well into the cell cytoplasm and 
extracellular space.   
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Figure 4.3: PAD2 expression in cells within CLS lesions of the murine 
mammary gland. Immunofluorescence staining of mammary gland adipose 
tissue sections with anti-PAD2 antibodies shows that cells within the CLS 
lesions appear to express PAD2. Nuclei are stained with DAPI. Nonspecific 
rabbit IgG was used as a negative control. 
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Figure 4.4: Extracellular trap-like structures within CLS lesions of the 
murine mammary gland stain positive for the histone H4Cit3 
modification. Immunostaining of mouse mammary gland adipose tissue with 
the anti-H4Cit3 antibody shows that extranuclear citrullinated histones appear 
to extend into the extracellular space between cells within CLS lesions. Arrow 
highlights nuclei from which the extracellular histones appear to originate. 
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Figure 4.5: Immunohistochemical localization of the histone H4Cit3 
modification within CLS lesions of the mammary gland. (A) Negative 
control showing adipose tissue sections stained with nonspecific rabbit IgG 
and hematoxylin counterstain. (B) - (D) Arrows indicate CLS lesions with 
positive immunostaining for the H4Cit3 modification. A higher magnification of 
the CLS lesion from B is given in C. 
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Outcomes from this study suggest that macrophages undergo ETosis 
following TNF- α stimulation in vitro and within mammary gland CLS lesions in 
obese mice. Our IF and IHC experiments using the anti-H4Cit3 antibody (a 
well validated marker for ET chromatin) finds that histone hypercitrullination is 
seen in extracellular chromatin in both RAW264.7 cells and in CLS 
macrophages, thus supporting the hypothesis that the observed ETosis is 
likely PAD-mediated. Additionally, we show that PAD2, but not PAD4, 
expression is robust within the nucleus of RAW264.7 cells and CLS-localized 
macrophages, thus identifying PAD2 as a strong candidate for catalyzing 
ETosis formation in macrophages. These preliminary findings provide support 
for the hypothesis that METs occur in CLS lesions of mammary gland adipose 
tissue from obese mice and lay the groundwork for future studies aimed at 
identifying a role for METs in CLS function. Given the close ties between PAD 
activity and inflammation, we favor the hypothesis that the release of 
hypercitrullinated histones from the macrophage nucleus into the extracellular 
space during MET formation plays a critical role in promoting inflammatory 
signaling pathways within microenvironment of mammary gland adipose tissue 
(Figure 4.6.). Experiments are currently underway to test this hypothesis.  
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Figure 4.6: Schematic illustration of the role of PAD2 mediated histone 
citrullination during MET formation in CLS lesions. (A) Macrophages 
infiltrate obese adipose tissue and surround dead adipocytes forming the CLS 
lesions. (B) TNF-α and other cytokines released from adipocytes may 
stimulate ETosis in these surrounding CLS macrophages thus promoting 
PAD2-mediated histone citrullination, chromatin decondensation and 
extracellular chromatin scaffold formation. (C) We hypothesize that the 
citrullinated histones released during MET formation may regulate the 
inflammatory microenvironment of mammary adipose tissue by influencing the 
macrophage infiltration and/or macrophage activation. 
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CHAPTER FIVE 
DISCUSSION – SUMMARY AND FUTURE ROLE FOR PAD2 IN 
CARCINOGENESIS AND REGULATION OF TUMOR INFLAMMATORY 
MICROENVIRONMENT 
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5.1 Summary of findings 
Previous research studies in our lab using MCF10AT breast cancer 
progression series cell lines, MCF10DCIS tumor spheroids, tumor xenografts 
and human breast cancer tissue samples found that PAD2 has a critical role in 
breast cancer progression. Prior to these studies even though PAD2 mediated 
protein citrullination has been associated with various autoimmune disease 
conditions, PAD4 was the only PAD family isozyme with an established role in 
carcinogenesis. The goal of this thesis research was to further elucidate the 
role of PAD2 in epithelial carcinogenesis using PAD2 overexpression tumor 
cell lines and a MMTV-FLAG-hPAD2 transgenic mouse model and evaluate 
how PAD2 may be playing a role in regulating inflammation associated with 
tumors and other chronic conditions such as obesity especially via a process 
termed extracellular chromatin trap release (“ETosis”). The results from this 
thesis research would help in advancing the significance of PAD2 as a novel 
therapeutic target and as a clinically relevant biomarker.  
 
To achieve the goal to study the role of PAD2 in epithelial carcinogenesis, we 
used an in vitro model of PAD2 overexpressing human SCC cell line , A431  
and an in vivo model of human PAD2 overexpression in mice under the 
regulation of MMTV promoter (Chapter 2). To achieve the goal to study the 
role of PAD2 in regulation of inflammatory microenvironment, we focused on 
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histone citrullination, chromatin decondensation and extracellular chromatin 
trap release (ETosis) mediated by PAD2 in immune cells, especially in 
macrophages using in vitro models such as RAW 264.7 macrophages and 
peritoneal macrophages and in vivo using human tongue SCC tissue sections 
and obese mammary adipose tissue sections (Chapter 3 and 4). Additional 
studies were also conducted to characterize comparative PAD2 expression in 
feline and canine mammary tumors which further validated the significance of 
PAD2 as a potential cancer biomarker and therapeutic target in these 
species1.   
 
In order to test whether PAD2 was sufficient for tumorigenesis in vivo, we 
generated a transgenic mouse model overexpressing human PAD2 under the 
control of the hormone-responsive MMTV-LTR promoter in FVB mice 
(Chapter 1). The immunohistochemical staining and western blotting showed 
that hPAD2 transgene is expressed in the mammary glands, but the MMTV-
FLAG-PAD2 mice failed to develop any mammary tumors. Given the 
knowledge that MMTV-LTR promoter while predominantly expressed in 
mammary and salivary gland, expression has also been reported in other 
tissues such as skin and ovaries 2, 3. An unexpected phenotype was observed 
in these mice and approximately 40% of the mice developed proliferative skin 
lesions after five months of age. The tumors expressed the transgenic form of 
FLAG-hPAD2 and showed increased expression for inflammatory cytokines 
such as IL6, IL8 homologues (MIP2 and LIX) and CCL17.  Histopathological 
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analysis showed that the proliferative skin lesions in these mice ranged from 
hyperplasia, dysplasia, and benign papillomas to invasive SCC.  
 
Intrigued by the skin pathology phenotype in PAD2 overexpressing mice, we 
conducted a two stage chemical carcinogenesis study using the DMBA-TPA 
model to further evaluate the predilection of MMTV-FLAG-hPAD2 mice to 
develop more invasive skin tumors and compare the histopathology of these 
tumors with the WT tumors which do not express the hPAD2 transgene 
(chapter 2). We found that a higher percentage of MMTV-FLAG-hPAD2 
developed skin papillomas at an earlier time point following the DMBA-TPA 
treatment compared to the WT mice. Also, the transgenic mice tumors were 
larger and showed more invasive macroscopic features. The histopathological 
features of these tumors were characterized and were blindly scored for 
inflammation, invasiveness, EMT morphology and mitotic index. The 
transgenic tumors received significantly higher scores for invasion and 
inflammation suggesting the potential of PAD2 transgene to assist malignant 
conversion and also had higher mitotic index compared to WT tumors 
suggesting the increased tumor cell proliferation in the presence of PAD2 
transgene. We studied the expression of inflammatory cytokines in these 
transgenic tumors in order to find an explanation of the highly inflamed tumor 
microenvironment present in these tumors. Interestingly we find that MMTV-
FLAG-hPAD2 tumors express significantly higher levels of IL8 homologues 
(MIP2 and LIX), IL6, CCL17 all of which may act as potential chemoattractants 
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for immune cells to the tumor microenvironment. hPAD2 levels highly 
positively correlated with these chemokine levels and negatively correlated 
with the cell adhesion marker, E-cadherin, expression. This study provided a 
direct comparison of PAD2 overexpressing tumors with WT tumors to evaluate 
the differences in tumor invasiveness and tumor associated inflammation 
using a transgenic mouse model.  
 
Our lab had previously published the critical role played by PAD4 isozyme in 
neutrophil extracellular trap release 4 via a phenomenon commonly called 
NETosis and is being currently widely studied 5-7. During the tumor tissue 
evaluations (chapter 2 and 3), we observed following immunohistochemical 
examination that tumor associated inflammatory cells especially macrophages 
are highly positive for PAD2 protein expression. There are only a few 
publications reporting the phenomenon of extracellular trap release by 
macrophages (METs) 8. In two related projects (chapter 3 and 4) we studied 
how PAD2 involved in MET release and characterized the presence of the 
METs in tumor associated inflammation and obesity associated inflammation. 
In chapter 4, using in vitro models of RAW 264.7 macrophage cell line and 
PAD2 knockout peritoneal macrophages we found that PAD2 is critical in 
functional MET release. These METs contained high levels of histone H4 
citrulline 3 (H4Cit3) modification in WT macrophages while the H4Cit3 levels 
were reduced in PAD2KO METs. In order to test the significance of METs in 
chronic inflammatory conditions such as tumor associated inflammation, we 
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co-immunostained human tongue SCC sections with MET markers such as 
anti-H4Cit3 antibody, Sytox Green DNA marker and macrophage markers 
(F4/80, CD68). Our findings confirm the presence of METs released by TAMs 
and we also observed that these METs are predominantly found surrounding 
invasive carcinoma cell islands. This novel study sheds light into the role of 
histone citrullination mediated by PAD2 in regulating the tumor inflammatory 
milieu. In order to test if this phenomenon of PAD2 regulated METs are 
present in other chronic inflammatory conditions, we chose obesity associated 
macrophage rich inflammation as a model. We characterized the 
macrophages present within the “CLS” (crown-like structure) lesions which are 
infiltrating macrophages surrounded a single dying adipocyte. Using co-
immunostaining for MET markers we showed that citrullinated histone rich 
MET structures exist in CLS lesions suggesting that PAD2 may also be 
playing a role in obesity-associated inflammation.  
 
Collectively, these studies provide strong experimental evidence establishing 
PAD2 as a potential novel oncogene, therapeutic target for cancer therapy 
and a regulator of obesity and tumor associated inflammation. However, there 
are some unanswered questions regarding the molecular mechanism by which 
PAD2 regulate tumor inflammation and invasion. Specifically, is there a 
transcriptional role for PAD2 in regulating E-cadherin / Vimentin and 
IL6/IL8/CCL17 expression? Also, is there a microenvironment effect which 
may be regulating PAD2 expression (e.g.: IFN-γ priming) in macrophages 
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which makes a subset of macrophages susceptible to MET release? Lastly, 
more experiments need to be done to further elucidate the role of PAD2 in 
tumorigenesis. The following sections will focus on several future directions 
and hypotheses to further explore the remaining questions.  
 
5.2 PAD2 may function differently in tumor cell regulation Vs immune 
cell ETosis 
The finding that PAD2 is involved in MET release raises the question – How 
PAD2 may mediate chromatin wide hypercitrullination in macrophages during 
ETosis while in mammary and skin carcinoma cells PAD2 seems to citrullinate 
specific gene promoters regulating EMT and cell proliferation?  One of the 
possible explanations lies in the drastic cell physiological changes involved in 
the ETosis process which ultimately results in the immune cell death 
especially the sharp upregulation of calcium influx. PADs are calcium 
dependent enzymes and the loss of calcium homeostasis and a sudden 
increase in intracellular calcium levels during ETosis may assist in rapid 
increase of PAD activity resulting in both nuclear and cytoplasmic protein 
hypercitrullination. There is a possibility that chromatin hypercitrullination 
during ETosis also requires priming of immune cells by other cytokines (e.g. 
IFN-γ) which will result in significant increase in PAD2 expression even before 
the cells enter ETosis and cause increased genome-wide binding of PAD2 to 
chromatin. These primed, PAD2 rich immune cells which are in a ready-to-
citrullinate stage may be highly responsive to ETosis stimuli and may form the 
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subset of immune cells initially releasing chromatin traps. 
In tumor and immune cell biology, PAD2 may play two distinct roles. 1. 
Transcriptional regulation of specific oncogenes and cytokines by citrullinating 
histones and transcriptional cofactors; 2. Direct citrullination of cytokines and 
ECM proteins leading to alteration in their structure and function. Studies have 
previously shown that citrullination of cytokines (eg. IL8) can lead to altered 
immune function 9. So the results observed in this thesis research should be 
further evaluated to differentiate the effect of direct cytokine and ECM protein 
citrullination (e.g. basement membrane proteins such as Collagen IV and 
fibronectin citrullination by PADs) and transcriptional regulation of these 
proteins by PAD2.  
5.3 Role of PAD2 in breast cancer progression and basement membrane 
integrity 
In a foundational study conducted in our lab to evaluate role of PAD2 in 
cancer progression, MCF10DCIS tumor xenograft bearing mice were treated 
with PAD inhibitor Cl-amidine and PAS stained tissue sections were evaluated 
for basement membrane integrity surrounding the ductal structures within this 
model of comedo-DCIS. Interestingly we found that basement membrane 
integrity was significantly reduced in PAD-inhibitor treated tumors compared to 
the PBS control treated group (Figure 5.1). This is a clinically significant 
finding and if explored further may prove to be yielding further insight into how 
PAD2 regulate cross talk between myoepithelial and luminal epithelial cells in 
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regulating basement membrane deposition 10-12. Also PAD2 mediated 
citrullination is known to play a role in cytoskeletal and intermediate filament 
fiber structures 13, 14. No literature is available on the role of PAD2 in regulating 
structure and 3-dimensional compactness of Collagen IV, laminin, or 
fibronectin which are important extracellular matrix components in carcinomas. 
Further in vitro studies are needed to specifically study the structural 
regulation of basement membrane components by citrullination mediated by 
PAD2 and how this may change the integrity of basement membrane during 
tumor progression to invasiveness. 
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Figure 5.1: Cl-amidine (PAD inhibitor) decreases the growth of 
MCF10DCIS tumors in a xenograft model of comedo-DCIS and enhances 
the basement membrane integrity 
MCF10DCIS cells (1 x 106) were injected subcutaneously into female nude 
(nu/nu) mice (Charles River). After 2 weeks of tumor growth (tumor volumes 
~100-200 mm3), mice were randomly treated with intraperitoneal injections of 
Cl-amidine at 50 mg/kg/day (n = 7) or PBS as a vehicle control (n = 7). PAS 
stained sections (10X, scale bar = 200 μm) from representative treated (I) and 
control tumors (II), arrows in (I) show an intact basement membrane (BM), 
while the arrow in (II) shows breaching of the BM with infiltrating leukocytes. 
BM integrity was also scored on a scale from 1-3 and scores were analyzed 
using Mann-Whitney-U test. The treated tumors have a lower score, indicating 
a higher level of BM integrity (* p < 0.05 MWU) (Figure obtained from 
McElwee JL et al, BMC cancer, 2012) 15 
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5.4 PAD2 mediated regulation of tumor associated inflammation and 
EMT 
PAD2 inhibitor Cl-amidine has been shown to alleviate the inflammatory 
symptoms in mouse models of colitis 16. PADs also regulate citrullination of 
vimentin which is shown to be important in autoimmune diseases such as 
rheumatoid arthritis 17. Increasing evidence supports the key role played by 
immune cells and inflammatory processes and recently tumor-promoting 
inflammation is also being defined as an emerging hallmark of cancer 18, 19. 
Many inflammatory mediators (e.g. cytokines/chemokines) are important for 
the growth and proliferation of pre-malignant cells 20. These mediators often 
activate oncogenic transcription factors, such as NFκB and STAT3 21-23.Our 
lab has found that PAD2 is critical in regulating HER2 expression in breast 
cancer cells and interestingly others have shown that HER2 in turn regulates 
IL6-STAT3 pathway activation 24. Activation of such an inflammatory loop sets 
the stage for further recruitment of inflammatory cells, endothelial cells, and 
growth factors involved in cancer cell survival, proliferation and invasion and 
eventual local and distant organ metastasis (Figure 5.2). PAD family members 
have previously been shown to promote the inflammatory microenvironment 
by regulating cytokine signaling in macrophages via citrullination of IKKγ, 
which controls NFκB expression activity 25. 
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In this thesis research I have shown that MMTV-FLAG-hPAD2 tumors show 
increased expression of IL6 and IL8 in both spontaneous skin tumors and in 
DMBA-TPA induced tumors. This pattern of cytokine upregulation was 
confirmed using an in vitro experiment in which hPAD2 was stably transfected 
in human SCC cell line, A431 cell line. Both IL6 and IL8 have been shown in 
previous studies to be important in tumor progression and play a critical role in 
tumor growth, angiogenesis, and EMT 26-30. Additional experiments are 
needed to identify the mechanism by which PAD2 regulates the expression of 
these inflammatory mediators. Future experiments may use ChIP to examine 
whether PAD2 binds to either IL6 or IL8 promoter. Also co-
immunoprecipitation (Co-IP) will be useful to examine whether there are any 
protein-protein interactions. 
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Figure 5.2: Tumor promoting inflammation as an emerging hallmark of 
cancer. Tumor associated inflammation assist in tumor progression by the 
release of paracrine signaling molecules such as EGF, VEGF and other 
proangiogenic factors. These cytokines further accelerates inflammation and 
matrix breakdown by a positive feedback look to recruit more immune cells, 
especially tumor associated macrophages and further supporting the tumor 
cell growth, neovascularization of the tumor and increased invasiveness of the 
tumor cells. 
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PAD2 overexpressing SCC cells also showed an increased migratory potential 
in transwell migration assay (Chapter 2). Cells undergoing the EMT 
phenomenon are often at the leading edge of invasive tumors. EMT is an 
important process during normal development and tumor invasion of epithelial 
tumors by which epithelial cells acquire mesenchymal, fibroblast-like 
properties, and show reduced intercellular adhesion and increased motility 
(Figure 5.3). Several oncogenic pathways have been implicated in regulation 
of EMT, including Src, Ras, Wnt/β-catenin, as well as downstream signaling 
from the PI3K-AKT-axis resulting from IGF1, as well as TGFβ, EGFR, and 
HER2 activation31-33. Further experiments will be needed to understand the 
mechanism by which PAD2 regulates EMT process. First, we need to look at 
whether PAD2 directly binds the E-cadherin promoter to regulate transcription. 
The stable A431-FLAG-PADI2 (A431-FP2) cell line used in experiments 
described in chapter 2 could be effectively used to analyze chromatin binding 
of PAD2. On a global level, it would be interesting to evaluate the 
transcriptomic differences between these two cell lines, to gain a deeper 
understanding of what genes are involved in PAD2-mediated oncogenesis and 
EMT regulation. 
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Figure 5.3: Overview of epithelial to mesenchymal transition (EMT). EMT 
describes a series of molecular and morphologic events that occur in epithelial 
cells during normal development or tumor progression. During EMT, normal 
polarized epithelial cells undergo morphologic and functional transition into 
more spindle shaped, migratory/invasive mesenchymal cells. The common 
markers for each transition stage are listed. E-cadherin expression is shown to 
be downregulated during this transition, while Vimentin levels are upregulated. 
E-cadherin suppressors (Snail and Slug), which bind to E-boxes in the 
promoter of E-cadherin leading to direct repression, are also upregulated. This 
process is usually accompanied by the degradation of the basement 
membrane which allows the local invasion and distant site metastasis of tumor 
cells. 
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(Figure 5.3). Several oncogenic pathways have been implicated in regulation 
of EMT, including Src, Ras, Wnt/β-catenin, as well as downstream signaling 
from the PI3K-AKT-axis resulting from IGF1, as well as TGFβ, EGFR, and 
HER2 activation31-33. Further experiments will be needed to understand the 
mechanism by which PAD2 regulates EMT process. First, we need to look at 
whether PAD2 directly binds the E-cadherin promoter to regulate transcription. 
The stable A431-FLAG-PADI2 (A431-FP2) cell line used in experiments 
described in chapter 2 could be effectively used to analyze chromatin binding 
of PAD2. On a global level, it would be interesting to evaluate the 
transcriptomic differences between these two cell lines, to gain a deeper 
understanding of what genes are involved in PAD2-mediated oncogenesis and 
EMT regulation. 
 
Stadler et al. have shown that PAD4 knockdown in xenografted MCF7 breast 
cancer cells leads to an increase in tumor invasiveness and associated EMT 
markers via the citrullination of GSK3β, which subsequently activates TGFβ 
signaling 34. We are in the process of using MCF10DCIS cells which are 
known to recapitulate invasive comedo-DCIS cancers when xenografted into 
nude mice to further study the role of PAD2 in EMT. Preliminary evidence 
shows that when PAD2 knockdown DCIS cells, E-cadherin is upregulated and 
cellular migration is decreased in MCF10DCIS cells. This suggests a direct 
relationship between PAD2 and E-cadherin expression. The xenografted 
MCF10DCIS tumors were used to further investigate this relationship. 
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Preliminary immunostaining experiments shown that Cl-amidine treated DCIS 
xenografts express higher levels of E-cadherin consistent with the PAD2 
knockdown DCIS cells. 
5.5 Role of PAD2 mediated extracellular chromatin trap release in DAMP 
pathway activation in tumors 
The process of cancer immune surveillance function to destroy the newly 
formed neoplastic cells such that most lesions capable of forming tumors are 
eliminated early during tumorigenesis by a process called “elimination” phase 
35-39. In some cases, a subpopulation of cancer cells “evolves” by acquiring 
capabilities of surviving the elimination phase. During this phase cancer cells 
gain immunomodulatory functions that help to decrease their immunogenicity 
and gain in immunoevasive abilities. An “equilibrium” phase follows during 
which the immune system encounters immunosusceptible cancer cells, and 
the immunoevasive subpopulation of tumor cells which are of low 
immunogenic properties. Immune selection actively eliminates the remaining 
highly immunogenic cancer cells while leading to escape and the clonal 
expansion of the low immunogenic cancer cells 36, 38. Dying cancer cells and 
immune cells can release or emit DAMPs (Damage Associated Molecular 
Patterns) which may act as danger signals.  
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Figure 5.4: The potential role of ETosis inflammatory microenvironment 
regulation and DAMP pathway activation. The extracellular traps released 
may play a critical role in cell signaling in adjacent tumor cells and immune 
cells. The MET scaffold when released into the circulation can act as a 
meshwork to assist in tumor thrombi formation. Histones and other nuclear 
proteins can lead to DAMP pathway activation and downstream signaling of 
RAGE (Receptor for advanced glycation end products), TLR4, TLR2 signaling 
axis thus releasing further inflammatory mediators. 
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Recent reports suggest that tumor cells undergoing accidental or primary 
necrosis do not generate a strong CD8+ T cell-dependent immune responses 
40. Even though a close association with cell death pathways and DAMP 
release exist, given our finding that ETosis and citrullinated histone rich METs 
exist in tumor microenvironment suggest the value of further experiments to 
specifically study the effect of METs in activating DAMP pathways in adjacent 
tumor cells and stromal cells (Figure 5.4). It has been shown that histones 
release from dying cells can activate TLR4 signaling and downstream NF-kB 
activation. Additional experiments in which METs are isolated from in vitro 
experiments, and exposing cancer cells and cultured macrophages to these 
MET containing medium will be useful in identifying the specific pathways 
activated by MET proteins. 
 
We also have initiated experiments to explore the role of ETosis in tumor 
associated inflammation in other type of human tumors such as breast cancer 
and Ewing’s sarcoma. Our preliminary results from IHC experiments using 
Ewing’s sarcoma tissue array indicate that PAD2 is highly expressed in a 
these tumors with a subset of tumors showing strong nuclear staining (Figure 
5.5). Morphologic features of several of the strongly stained cells within these 
tumor tissue cores suggest high PAD2 expression in immune cells associated 
with tumor inflammation. It is also interesting to note that there is a recent 
study showing the abundance of extracellular chromatin traps in Ewing’s 
sarcoma even though that study did not address the potential role of PAD2 in  
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Figure 5.5: Ewing’s sarcoma as a model to study the role of PAD2 
mediated ETosis in regulating tumor associated inflammation. Ewing’s 
sarcoma tumor tissue array obtained from human patients (collaborator – Dr. 
Jeffrey Toretsky, Georgetown University) and immunostained to test for PAD2 
expression. There is moderate to strong cytoplasmic expression of PAD2 in 
these cases (Fig 5.5A and 5.5C) while some cases show low expression (Fig 
6.5D). Interestingly a subset of cases showed predominantly nuclear 
localization of PAD2 (Fig 5.5B). 
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Figure 5.6: 4-NQO chemical carcinogenesis model to study oral tumor 
progression and inflammation. WT, PAD2KO and MMTV-FLAG-hPAD2 
mice will be treated with 4-NQO administration for 12 weeks followed by 
ethanol treatment. Another set of mice will receive vehicle treatment. 
Preliminary characterization of this model in our lab suggests that this is a 
useful model to study oral tumor progression and tumor associated 
inflammation. The tissue sections for the preliminary IHC staining experiments 
to detect PAD2 and H4Cit3 levels were obtained from our collaborator Dr. 
Lorraine Gudas, Weill School of Medicine. 
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mediating this phenomenon 41. Future experiments in our lab will focus on 
immunostaining and confocal imaging of breast cancer sections from human 
patients using ET markers and macrophage markers. 
5.6 4-NQ-O oral carcinogenesis model to study the role of PAD2 in head 
and neck tumor-associated inflammation 
In this thesis research we provide strong evidence for the role of METs in 
tumor associated inflammation in tongue SCC. Additional experiments using a 
mouse model of oral carcinogenesis will be very informative to specifically 
show the role of PAD2 in regulation of oral carcinoma progression and 
associated inflammation. We plan to use a well characterized chemical 
carcinogenesis model to induce tongue tumors in mice called the 4-NQO – 
alcohol mediated carcinogenesis 42. Preliminary IHC studies conducted in our 
lab show that PAD2 is strongly expressed in immune cells associated with 
tongue papillomas in induced by 4-NQO and that the MET associated histone 
citrullination (H4Cit3) is present in a subset of immune cells associated with 
tongue tumors. In this model, the mice will be treated with 100 µg/ml 4-NQO or 
the vehicle control for 12 weeks and then with 20% ethanol or water for 12 
more weeks (Figure 5.6). The experimental groups will include WT, MMTV-
FLAG-hPAD2 mice and PAD2 knockout mice. This in vivo experiment will be 
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valuable in further understanding the role of inflammatory cells expressing 
PAD2 in oral carcinoma progression. 
5.7 Reflections on the role of PAD2 and CLS METs in obesity-associated 
inflammation and its clinical relevance 
Outcomes from our study (Chapter 5) in obesity associated subclinical 
inflammation suggested that macrophages undergo ETosis following TNF-α 
and other paracrine signal stimulation in vitro and within mammary gland CLS 
lesions in obese mice. Histone hypercitrullination marks were evident in 
extracellular chromatin in both RAW264.7 cells and in CLS macrophages 
using IF-confocal imaging and IHC methods which supported the hypothesis 
that the observed ETosis is likely PAD-mediated. We also showed that PAD2, 
but not PAD4, expression is robust within the nucleus of RAW264.7 cells and 
CLS-localized macrophages, thus identifying PAD2 as a strong candidate for 
mediator of ETosis process in macrophages. In order to further test the 
hypothesis of METs are modifying adipose tissue microenvironment future 
experiments will be needed using in vitro coculture systems using 
macrophages and cultured adipocytes. Peritoneal macrophages from PAD2 
knockout mice can be used for this purpose to specifically show the role of 
PAD2 in macrophage function in CLS lesions.  
 
 
 
   201 
 
 
 
 
 
 
 
Figure 5.7: The potential role of ETosis obesity-associated inflammatory 
microenvironment regulation. CLS lesions represent subclinical 
“smoldering” foci of inflammation consisting of macrophages which surround 
dying adipocytes. We found that these macrophages release METs which 
contain high levels of citrullinated histones. Histones are known to upregulate 
TLR4 signaling in immune cells. Future experiments will focus on identifying 
the potential of using citrullinated histones and other citrullinated proteins in 
patient serum samples as a clinical biomarker in order to detect obesity 
associated inflammation. 
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The hypercitrullinated histones and other nuclear proteins from the 
macrophage nucleus released into the extracellular space during MET 
formation may play a critical role in promoting inflammatory signaling 
pathways within microenvironment of mammary gland adipose tissue (Figure 
5.7). Given the lack of strong biomarkers to differentiate the amount of 
inflammation within obese adipose tissue in clinical cases 43, the idea of using 
a method of detection to quantitate citrullinated histones and other nuclear 
protein in the patient serum samples is very promising. With this translational 
goal in mind, we are in the process of testing a newly developed fluorescence 
based system to detect citrullinated proteins in the serum samples. 
 
One of our collaborators, Dr. Paul Thompson at Scripps Institute, has recently 
developed a citrulline specific chemical probe rhodamine‐phenylglyoxal (Rh‐
PG), which can be used to investigate the array of protein citrullination in cells 
and tissue extracts. A nonbiased evaluation of protein citrullination levels in 
obese mice and human patients’ serum samples using this novel, high 
throughput phenylglycoxal-based fluorescent probe system can be promising. 
Previously described methods for studying citrullination include the Color 
Development Reagent (COLDER) assay and a commercially available Anti‐
Citrulline (Modified) Detection Kit (ACM kit, Millipore, Billerica, MA). But this 
high throughput Rh-PG method provides superior sensitivity over these 
existing methods. The Rh-PG method is based on the chemoselective reaction 
that occurs between glyoxals and either citrulline or arginine under acidic or 
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basic conditions, respectively. This system may offer a sensitive method to 
detect citrullinated proteins in obese patient samples and evaluate if this can 
be used as a clinical biomarker for obesity associated inflammation. 
5.8 Connecting the dots – Current understanding of PAD2’s role in 
epithelial carcinogenesis and tumor-associated inflammation 
The objective of this thesis research was to gain insight into the potential 
function of PAD2 in cancer progression and inflammation. This study has 
helped in advancing our understanding of PAD2 biology and helped to 
strongly establish a role for PAD2 as a novel oncogene, a therapeutic target 
for cancer therapy and a regulator of tumor and obesity associated 
inflammation. An overview of the potential functions of PAD2 in cancer and 
inflammation based on the experimental evidence presented in this thesis is 
reviewed in figure 5.8. We show here for the first time that PAD2 is capable of 
inducing spontaneous tumors in a PAD2 overexpressing transgenic mouse 
model. We also show that PAD2 overexpressing mice develop more invasive 
tumors with features of increased tumor associated inflammation. Two critical 
processes associated with tumor progression, EMT and onco-inflammation are 
enhanced in these transgenic tumors.  This research study also lead the way 
in further understanding the role of PAD2 in the process of ETosis and how 
chromatin traps can modify chronic inflammatory conditions such as tumor-
associated and obesity associated inflammation. These critical insights extend 
the role of PAD2 into clinically significant disease areas involving cancer and 
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metabolic disease and provide a strong basis for future clinically oriented 
research studies. 
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Figure 5.8: Overview of the potential role of PAD2 in cancer progression 
and regulation of inflammatory microenvironment. This thesis research 
and other studies in our lab have shown that PAD2 plays a critical role in 
breast cancer and skin cancer pathogenesis. One of the mechanisms by 
which PAD2 regulate ER-target gene recruitment is via Histone H3 arginine 26 
(H3R26) citrullination. This also leads to upregulation of HER2. Using the 
MMTV-FLAG-hPAD2 mouse model, we show that PAD2 overexpression can 
lead to skin carcinogenesis and increased amount of tumor associated 
inflammation. PAD2 overexpression resulted in upregulation of 
cytokine/chemokine expression such as IL8, IL6 and CCL17. PAD2 
upregulation also favor the EMT phenomenon and lead to downregulation of 
E-Cadherin. Furthermore, PAD2 is critical in macrophage extracellular trap 
formation and these traps are enriched with citrullinated histones. We 
characterize the features of macrophage released chromatin traps within 
tumor associated inflammation and obesity associated inflammatory 
microenvironment. Our study emphasizes the significance of PAD2 as a 
biomarker and therapeutic target in epithelial tumor progression and tumor- 
and obesity-associated inflammation. 
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